<SEC-DOCUMENT>0001193125-18-017992.txt : 20180124
<SEC-HEADER>0001193125-18-017992.hdr.sgml : 20180124
<ACCEPTANCE-DATETIME>20180124082503
ACCESSION NUMBER:		0001193125-18-017992
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		8
CONFORMED PERIOD OF REPORT:	20180123
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180124
DATE AS OF CHANGE:		20180124

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SYNLOGIC, INC.
		CENTRAL INDEX KEY:			0001527599
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				261824804
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37566
		FILM NUMBER:		18544050

	BUSINESS ADDRESS:	
		STREET 1:		200 SIDNEY STREET
		STREET 2:		SUITE 320
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617-401-9975

	MAIL ADDRESS:	
		STREET 1:		200 SIDNEY STREET
		STREET 2:		SUITE 320
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Mirna Therapeutics, Inc.
		DATE OF NAME CHANGE:	20110809
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d514974d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): January&nbsp;23, 2018 </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>SYNLOGIC, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-37566</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">26-1824804</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>200 Sidney St., Suite 320</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cambridge, MA</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>02139</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(617) <FONT STYLE="white-space:nowrap">401-9975</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
Name or Former Address, if Changed Since Last Report) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 (17 CFR <FONT STYLE="white-space:nowrap">&#167;240.12b-2).</FONT> </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging Growth Company&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9746; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;1.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Entry Into a Material Definitive Agreement. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;23, 2018, Synlogic,&nbsp;Inc. (the
&#147;Company&#148;) entered into an underwriting agreement (the &#147;Underwriting Agreement&#148;) with Leerink Partners LLC and Piper Jaffray&nbsp;&amp; Co., as representatives of the several underwriters named therein (the
&#147;Underwriters&#148;), relating to the underwritten public offering of 5,130,000 shares of the Company&#146;s common stock, par value $0.001 per share (the &#147;Offering&#148;). The price to the public in the Offering was $9.75 per share. The
net proceeds to the Company from the Offering are expected to be approximately $46.7 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. The Offering is scheduled to close on
or about January&nbsp;26, 2018, subject to customary closing conditions. In addition, under the terms of the Underwriting Agreement, the Company granted the Underwriters an option, exercisable for 30 days, to purchase up to 769,500 additional shares
of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to
closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), other obligations of the parties and termination provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Offering was made pursuant to the Company&#146;s effective registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> (Registration
Statement <FONT STYLE="white-space:nowrap">No.&nbsp;333-220948)</FONT> previously filed with the Securities and Exchange Commission (&#147;SEC&#148;) and a related prospectus supplement and accompanying prospectus. The Underwriting Agreement is
filed as Exhibit&nbsp;1.1 to this report and is incorporated herein by reference. The foregoing description of the terms of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit. A
copy of the opinion of Mintz, Levin, Cohn, Ferris, Glovsky&nbsp;&amp; Popeo, P.C. relating to the legality of the issuance and sale of the shares in the Offering is attached as Exhibit&nbsp;5.1 hereto. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.02</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Results of Operations and Financial Condition. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;23, 2018, the Company filed a
preliminary prospectus supplement with the SEC in which it disclosed that it had estimated cash, cash equivalents and marketable securities of approximately $87.0&nbsp;million as of December&nbsp;31, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The estimated cash, cash equivalents, and marketable securities as of December&nbsp;31, 2017 are preliminary and may change, are based on information
available to management as of January&nbsp;23, 2018, and are subject to completion by management of the financial statements as of and for the year ended December&nbsp;31, 2017. There can be no assurance that the Company&#146;s cash, cash
equivalents, and marketable securities as of December&nbsp;31, 2017 will not differ from these estimates, including as a result of <FONT STYLE="white-space:nowrap">quarter-end</FONT> closing and any such changes could be material. This data could
change as a result of further review. Complete annual results will be included in the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;7.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Regulation FD Disclosure. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the Company&#146;s current plans, the Company believes that its
existing cash, cash equivalents, and marketable securities, together with the net proceeds of the Offering, will be sufficient to enable the Company to fund its operating expenses and capital expenditure requirements through 2019. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;23, 2018, the Company issued a press release announcing that it had
commenced the Offering. On January&nbsp;24, 2018, the Company issued a press release announcing that it had priced the Offering. Copies of these press releases are attached as Exhibits 99.1 and 99.2 hereto, respectively, and the information
contained therein is incorporated herein by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This report contains &#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A
of the Securities Act and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, including statements regarding the Company&#146;s expectations with respect to the Offering, including its ability to complete the Offering and its
expected and intended use of proceeds from the Offering.&nbsp;These and any other forward-looking statements in this report are based on management&#146;s current expectations of future events and are subject to a number of risks and uncertainties
that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties associated with
market conditions and the satisfaction of customary closing conditions related to the proposed offering, as well as risks and uncertainties detailed in the Company&#146;s periodic filings with the SEC, including but not limited to the
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company&#146;s <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> for the quarter ended September&nbsp;30, 2017, and from time to time the Company&#146;s other investor communications. The
Company is providing the information in this report as of this date and does not undertake any obligation to update any forward-looking statements contained in this report as a result of new information, future events or otherwise, except to the
extent required by law. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(d)&nbsp;Exhibits </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d514974dex11.htm">Underwriting Agreement, dated January&nbsp;23, 2018, among Synlogic, Inc. and Leerink Partners LLC and Piper Jaffray&nbsp;&amp; Co., as representatives of the several underwriters named therein.
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d514974dex51.htm">Opinion of Mintz, Levin, Cohn, Ferris, Glovsky&nbsp;&amp; Popeo, P.C. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d514974dex51.htm">Consent of Mintz, Levin, Cohn, Ferris, Glovsky&nbsp;&amp; Popeo, P.C. (included in Exhibit 5.1) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d514974dex991.htm">Press Release, dated January&nbsp;23, 2018 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d514974dex992.htm">Press Release, dated January&nbsp;24, 2018 </A></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date: January&nbsp;24, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Synlogic,&nbsp;Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Todd Shegog</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Todd Shegog</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d514974dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SYNLOGIC, INC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(a Delaware
corporation) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5,130,000 Shares of Common Stock </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDERWRITING AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">January&nbsp;23, 2018 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Piper Jaffray&nbsp;&amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">as Representatives of the several
Underwriters </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Leerink Partners LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">299 Park Avenue,
21st Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10176 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Piper Jaffray&nbsp;&amp;
Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">800 Nicollet Mall </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Minneapolis, Minnesota 55402 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Synlogic, Inc., a
Delaware corporation (the &#147;<U>Company</U>&#148;), confirms its agreement with Leerink Partners LLC (&#147;<U>Leerink</U>&#148;), Piper Jaffray&nbsp;&amp; Co. (&#147;Piper Jaffray&#148;) and each of the other Underwriters named in
<U>Schedule</U><U></U><U>&nbsp;A</U> hereto (collectively, the &#147;<U>Underwriters</U>,&#148; which term shall also include any underwriter substituted as hereinafter provided in Section&nbsp;10 hereof), for which Leerink and Piper Jaffray are
acting as representatives (in such capacity, the &#147;<U>Representatives</U>&#148;), with respect to (i)&nbsp;the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of
common stock, par value $0.001 per share, of the Company (&#147;<U>Common Stock</U>&#148;) set forth in <U>Schedule</U><U></U><U>&nbsp;A</U> hereto and (ii)&nbsp;the grant by the Company to the Underwriters, acting severally and not jointly, of the
option described in Section&nbsp;2(b) hereof to purchase all or any part of 769,500 additional shares of Common Stock. The aforesaid 5,130,000 shares of Common Stock (the &#147;<U>Initial Securities</U>&#148;) to be purchased by the Underwriters and
all or any part of the 769,500 shares of Common Stock subject to the option described in Section&nbsp;2(b) hereof (the &#147;<U>Option Securities</U>&#148;) are herein called, collectively, the &#147;<U>Securities</U>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company understands that the Underwriters propose to make a public offering of the Securities as soon as the Representatives deems
advisable after this Underwriting Agreement (this &#147;<U>Agreement</U>&#148;) has been executed and delivered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has filed
with the Securities and Exchange Commission (the &#147;<U>Commission</U>&#148;) a shelf registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> (No. <FONT STYLE="white-space:nowrap">333-220948),</FONT> covering the public
offering and sale of certain securities, including the Securities, under the Securities Act of 1933, as amended (the &#147;<U>1933 Act</U>&#148;) and the rules and regulations of the Commission promulgated thereunder (the &#147;<U>1933 Act
Regulations</U>&#148;), which shelf registration statement was declared effective on October&nbsp;25, 2017. Such registration statement, as of any time, means such registration statement as amended by any post-effective amendments thereto at such
time, </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including the exhibits and any schedules thereto at such time, the documents incorporated or deemed to be incorporated by reference therein at such time pursuant to Item 12 of Form <FONT
STYLE="white-space:nowrap">S-3</FONT> under the 1933 Act and the documents otherwise deemed to be a part thereof as of such time pursuant to Rule 430B under the 1933 Act Regulations (&#147;Rule 430B&#148;), is referred to herein as the
&#147;Registration Statement;&#148; provided, however, that the &#147;Registration Statement&#148; without reference to a time means such registration statement as amended by any post-effective amendments thereto as of the time of the first contract
of sale for the Securities, which time shall be considered the &#147;new effective date&#148; of such registration statement with respect to the Securities within the meaning of paragraph (f)(2) of Rule 430B, including the exhibits and schedules
thereto as of such time, the documents incorporated or deemed incorporated by reference therein at such time pursuant to Item 12 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the 1933 Act and the documents otherwise deemed to be a part
thereof as of such time pursuant to the Rule 430B. Any registration statement filed pursuant to Rule 462(b) of the 1933 Act Regulations in connection with the offer and sale of the Securities is herein called the &#147;<U>Rule 462(b) Registration
Statement</U>&#148; and, after such filing, the term &#147;Registration Statement&#148; shall include the Rule 462(b) Registration Statement. Each preliminary prospectus used in connection with the offering of the Securities, including the documents
incorporated or deemed to be incorporated by reference therein pursuant to Item 12 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the 1933 Act, are collectively referred to herein as a &#147;preliminary prospectus.&#148; Promptly after
execution and delivery of this Agreement, the Company will prepare and file a final prospectus relating to the Securities in accordance with the provisions of Rule 424(b) under the 1933 Act Regulations (&#147;Rule 424(b)&#148;). The final
prospectus, in the form first furnished or made available to the Underwriters for use in connection with the offering of the Securities, including the documents incorporated or deemed to be incorporated by reference therein pursuant to Item 12 of
Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the 1933 Act, are collectively referred to herein as the &#147;Prospectus.&#148; For purposes of this Agreement, all references to the Registration Statement, any preliminary prospectus, the
Prospectus or any amendment or supplement to any of the foregoing shall be deemed to include the copy filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval system (or any successor system)(&#147;EDGAR&#148;).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Agreement: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Applicable Time&#148; means 7:45 P.M., New York City time, on January&nbsp;23, 2018 or such other time as agreed by the
Company and the Representatives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;General Disclosure Package&#148; means any Issuer General Use Free Writing
Prospectuses issued at or prior to the Applicable Time, the most recent preliminary prospectus (including any documents incorporated therein by reference) that is distributed to investors prior to the Applicable Time and the information included on
<U>Schedule</U><U></U><U>&nbsp;B</U><U><FONT STYLE="white-space:nowrap">-1</FONT></U> hereto, all considered together. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Issuer Free Writing Prospectus&#148; means any &#147;issuer free writing prospectus,&#148; as defined in Rule 433 of the
1933 Act Regulations (&#147;<U>Rule 433</U>&#148;), including without limitation any &#147;free writing prospectus&#148; (as defined in Rule 405 of the 1933 Act Regulations (&#147;<U>Rule 405</U>&#148;)) relating to the Securities that is
(i)&nbsp;required to be filed with the Commission by the Company, (ii)&nbsp;a &#147;road show for an offering that is a written communication&#148; within the meaning of Rule 433(d)(8)(i), whether or not required to be filed with the Commission, or
(iii)&nbsp;exempt from filing with the Commission pursuant to Rule 433(d)(5)(i) because it contains a description of the Securities or of the offering that does not reflect the final terms, in each case in the form filed or required to be filed with
the Commission or, if not required to be filed, in the form retained in the Company&#146;s records pursuant to Rule 433(g). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Issuer General Use Free Writing Prospectus&#148; means any Issuer Free Writing Prospectus that is intended for general
distribution to prospective investors (other than a &#147;<I>bona fide</I> electronic road show,&#148; as defined in Rule 433 (a &#147;<U>Bona Fide Electronic Road Show</U>&#148;)), as evidenced by its being specified in
<U>Schedule</U><U></U><U>&nbsp;B</U><U><FONT STYLE="white-space:nowrap">-2</FONT></U> hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Issuer Limited Use Free Writing Prospectus&#148; means any Issuer Free
Writing Prospectus that is not an Issuer General Use Free Writing Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">&#147;Testing-the-Waters</FONT></FONT> Communication&#148; means any oral or written communication with potential investors undertaken in reliance on Section&nbsp;5(d) of the 1933 Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communication&#148; means any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that is a written communication within the meaning of Rule 405 under the 1933 Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All references in this Agreement to financial statements and schedules and other information which is &#147;contained,&#148;
&#147;included&#148; or &#147;stated&#148; (or other references of like import) in the Registration Statement, any preliminary prospectus or the Prospectus shall be deemed to include all such financial statements and schedules and other information
incorporated or deemed incorporated by reference in the Registration Statement, any preliminary prospectus or the Prospectus, as the case may be, prior to the execution and delivery of this Agreement; and all references in this Agreement to
amendments or supplements to the Registration Statement, any preliminary prospectus or the Prospectus shall be deemed to include the filing of any document under the Securities Exchange Act of 1934, as amended (the &#147;<U>1934 Act</U>&#148;), and
the rules and regulations promulgated thereunder (the &#147;<U>1934 Act Regulations</U>&#148;), incorporated or deemed to be incorporated by reference in the Registration Statement, such preliminary prospectus or the Prospectus, as the case may be,
at or after the execution and delivery of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations and Warranties</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Representations and Warranties by the Company</I>. The Company represents and warrants to each Underwriter as of
the date hereof, the Applicable Time, the Closing Time (as defined below) and any Date of Delivery (as defined below), and agrees with each Underwriter, as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration Statement</U><U> and Prospectuses</U>. The Company meets the requirements for use of
Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the 1933 Act. Each of the Registration Statement and any amendment thereto has become effective under the 1933 Act. No stop order suspending the effectiveness of the Registration Statement or
any post-effective amendment thereto has been issued by the Commission under the 1933 Act, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been issued by the Commission and no proceedings for any of
those purposes have been instituted by the Commission or are pending or, to the Company&#146;s knowledge, contemplated by the Commission. The Company has complied with each request (if any) from the Commission for additional information. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the Registration Statement and any post-effective amendment thereto, at the time of its effectiveness and at each
deemed effective date with respect to the Underwriters pursuant to Rule 430B(f)(2) under the 1933 Act Regulations, complied in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations. Each preliminary prospectus, the
Prospectus and any amendment or supplement thereto, at the time each was filed with the Commission, complied in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations. Each preliminary prospectus delivered to the
Underwriters for use in connection with the offering and the Prospectus was or will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T.</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The documents incorporated or deemed to be incorporated by reference in the
Registration Statement and the Prospectus, when they became effective or at the time they were or hereafter are filed with the Commission, complied and will comply in all material respects with the requirements of the 1934 Act and the 1934 Act
Regulations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Registration Statement, any preliminary prospectus and the Prospectus, and
the filing of the Registration Statement, any preliminary prospectus and the Prospectus with the Commission have been duly authorized by and on behalf of the Company, and the Registration Statement has been duly executed pursuant to such
authorization. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Accurate Disclosure</U>. Neither the Registration Statement nor any
amendment thereto, at its effective time, at the Closing Time or at any Date of Delivery, contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material fact required to be stated
therein or necessary to make the statements therein not misleading. As of the Applicable Time, none of (A)&nbsp;the General Disclosure Package, (B)&nbsp;any individual Issuer Limited Use Free Writing Prospectus, when considered together with the
General Disclosure Package, nor (C)&nbsp;any individual Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, when considered together with the General Disclosure Package, included,
includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.
Neither the Prospectus nor any amendment or supplement thereto (including any prospectus wrapper), as of its issue date, at the time of any filing with the Commission pursuant to Rule 424(b), at the Closing Time or at any Date of Delivery, included,
includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.
The documents incorporated or deemed to be incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus, at the time the Registration Statement became effective or when such documents incorporated by
reference were filed with the Commission, as the case may be, when read together with the other information in the Registration Statement, the General Disclosure Package or the Prospectus, as the case may be, did not and will not include an untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The representations and warranties in this subsection shall not apply to statements in or omissions from the Registration
Statement (or any amendment thereto), the General Disclosure Package or the Prospectus (or any amendment or supplement thereto, including any prospectus wrapper) made in reliance upon and in conformity with written information furnished to the
Company by any Underwriter through the Representatives expressly for use therein. For purposes of this Agreement, the only information so furnished shall be the information contained in the first paragraph under the heading
&#147;Underwriting&#151;Commissions and Discounts&#148;, second, third and fourth paragraphs under the heading &#147;Underwriting&#151;Price Stabilization, Short Positions and Penalty Bids&#148; and the information under the heading
&#147;Underwriting&#151;Electronic Distributions,&#148; in each case contained in the Prospectus (collectively, the &#147;<U>Underwriter Information</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Issuer Free Writing Prospectuses</U>. No Issuer Free Writing Prospectus conflicts or will
conflict with the information contained in the Registration Statement or the Prospectus, including any document incorporated by reference therein, and any preliminary or other prospectus deemed to be a part thereof that has not been superseded or
modified. No filing of any &#147;road show&#148; (as defined in Rule 433(h)) is required in connection with the offering of the Securities. Any Issuer Free Writing Prospectus that the Company is required to file pursuant to Rule 433(d) under the
Securities Act has been, or will be, filed with the Commission in accordance with the requirements of the 1933 Act and the 1933 Act Regulations. Each Issuer Free Writing Prospectus that the Company has filed, or is required to file, pursuant to Rule
433(d) under the 1933 Act or that was </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
prepared by or behalf of or used or referred to by the Company complies or will comply in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations. Except for the
Issuer Free Writing Prospectuses, if any, identified in <U>Schedule <FONT STYLE="white-space:nowrap">B-2</FONT></U> hereto, and electronic road shows, if any, each furnished to the Representatives before first use, the Company has not prepared, used
or referred to, and will not, without the prior consent of the Representatives, prepare, use or refer to, any issuer free writing prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;
<U><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Materials</U>. The Company (A)&nbsp;has not engaged in any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication other than <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications with the
consent of the Representatives with entities that it has reasonable basis to believe are qualified institutional buyers within the meaning of Rule 144A under the 1933 Act or institutions that are accredited investors within the meaning of Rule 501
under the 1933 Act and (B)&nbsp;has not authorized anyone other than the Representatives to engage in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. The Company reconfirms that the
Representatives have been authorized to act on its behalf in undertaking <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications authorized by the Company. The Company has not distributed any
Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications other than those listed on <U>Schedule <FONT STYLE="white-space:nowrap">B-3</FONT></U> hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;<U>Company Not Ineligible Issuer</U>. At the time of filing the Registration Statement and any
post-effective amendments thereto, at the earliest time thereafter that the Company or another offering participant made a <I>bona fide</I> offer (within the meaning of Rule 164(h)(2) of the 1933 Act Regulations) of the Securities and at the date
hereof, the Company was not and is not an &#147;ineligible issuer,&#148; as defined in Rule 405, without taking account of any determination by the Commission pursuant to Rule 405 that it is not necessary that the Company be considered an ineligible
issuer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp;<U>Emerging Growth Company Status.</U> From the time of the initial filing of the
Registration Statement with the Commission (or, if earlier, the first date on which the Company engaged directly or through any Person authorized to act on its behalf in any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication) through the date hereof, the Company has been and is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the
1933 Act (an &#147;<U>Emerging Growth Company</U>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Independent Accountants</U>. The
accountants who certified the financial statements and supporting schedules included in the Registration Statement, the General Disclosure Package and the Prospectus are independent public accountants with respect to the Company or Mirna
Therapeutics, Inc., as applicable, as required by the 1933 Act, the 1933 Act Regulations, the 1934 Act, the 1934 Act Regulations and the Public Company Accounting Oversight Board (United States). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Financial Statements; <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Financial Measures</U>.
The financial statements included or incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus, together with the related schedules and notes, comply as to form in all material respects with
Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the 1933 Act and present fairly, in all material respects, the financial position of the Company and its consolidated Subsidiaries (as defined below) at the dates indicated and the
statement of operations, stockholders&#146; equity and cash flows of the Company and its consolidated Subsidiaries for the periods specified; said financial statements have been prepared in conformity in all material respects with U.S. generally
accepted accounting principles (&#147;<U>GAAP</U>&#148;) applied on a consistent basis throughout the periods involved, except, in the case of unaudited, interim financial statements, subject to normal
<FONT STYLE="white-space:nowrap">year-end</FONT> adjustments and the exclusion of certain footnotes. The supporting schedules, if any, present fairly, in all material respects, in accordance with GAAP the information required to be stated therein.
The selected financial data and the summary financial information included in the Registration Statement, the General Disclosure Package and the Prospectus present fairly, in all material respects, the information shown therein and have been
compiled on a basis consistent with that of the audited financial statements included therein. The pro forma financial statements and the related notes thereto included in the Registration Statement, the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
General Disclosure Package and the Prospectus present fairly the information shown therein, have been prepared in accordance with the Commission&#146;s rules and guidelines with respect to pro
forma financial statements and have been properly compiled on the bases described therein, and the assumptions used in the preparation thereof are reasonable and the adjustments used therein are appropriate to give effect to the transactions and
circumstances referred to therein. Except as included therein, no historical or pro forma financial statements or supporting schedules are required to be included or incorporated by reference in the Registration Statement, the General Disclosure
Package or the Prospectus under the 1933 Act or the 1933 Act Regulations. All disclosures contained in the Registration Statement, the General Disclosure Package or the Prospectus, or incorporated by reference therein, regarding <FONT
STYLE="white-space:nowrap">&#147;non-GAAP</FONT> financial measures&#148; (as such term is defined by the rules and regulations of the Commission) comply with Regulation G of the 1934 Act, and Item 10 of Regulation
<FONT STYLE="white-space:nowrap">S-K,</FONT> to the extent applicable. The interactive data in eXtensible Business Reporting Language incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus fairly
presents the information called for in all material respects and has been prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix)&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance with the Sarbanes-Oxley Act of 2002</U>. There is and has been no failure on the part
of the Company or any of the Company&#146;s directors or officers, in their capacities as such, to comply in all material respects with any applicable provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated in
connection therewith, including Section&nbsp;402 related to loans and Sections 302 and 906 related to certifications. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Material Adverse Change in Business</U>. Except as otherwise stated therein, since the
respective dates as of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus, (A)&nbsp;there has been no material adverse change in the condition, financial or otherwise, or in the earnings,
business affairs or business prospects of the Company and its Subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business (a &#147;<U>Material Adverse Effect</U>&#148;), (B)&nbsp;there have been no
transactions entered into by the Company or its Subsidiaries, other than those in the ordinary course of business, which are material with respect to the Company and its Subsidiaries considered as one enterprise, (C)&nbsp;there have been no material
liabilities or obligations, direct or contingent, entered into by the Company or any of its Subsidiaries and (D)&nbsp;there has been no dividend or distribution of any kind declared, paid or made by the Company on any class of its capital stock.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi)&nbsp;&nbsp;&nbsp;&nbsp;<U>Good Standing of the Company</U>. The Company has been duly organized and is validly
existing as a corporation in good standing under the laws of the State of Delaware and has corporate power and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the General
Disclosure Package and the Prospectus and to enter into and perform its obligations under this Agreement; and the Company is duly qualified as a foreign corporation to transact business and is in good standing in each other jurisdiction in which
such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to be so qualified or to be in good standing would not result in a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Good Standing of the Company&#146;s Subsidiaries</U>. Each subsidiary of the Company
(collectively, the &#147;<U>Subsidiaries</U>&#148;) has been duly organized and is validly existing in good standing under the laws of the jurisdiction of its incorporation or organization, has corporate or similar power
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the General Disclosure Package and the Prospectus and is duly
qualified to transact business and is in good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to be so qualified or
to be in good standing would not result in a Material Adverse Effect. Except as otherwise disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, all of the issued and outstanding capital stock of each Subsidiary
has been duly authorized and validly issued, is fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and is owned by the Company, directly or through Subsidiaries, free and clear of any security interest, mortgage, pledge, lien,
encumbrance, claim or equity. None of the outstanding shares of capital stock of any Subsidiary was issued in violation of the preemptive or similar rights of any securityholder of such Subsidiary. The only Subsidiaries are the entities listed on
<U>Schedule C</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Capitalization</U>. The authorized, issued and outstanding shares of
capital stock of the Company are as set forth in the Registration Statement, the General Disclosure Package and the Prospectus in the column entitled &#147;Actual&#148; under the caption &#147;Capitalization&#148; (except for subsequent issuances,
if any, (A)&nbsp;pursuant to this Agreement, (B)&nbsp;pursuant to reservations, agreements or employee benefit plans referred to in the Registration Statement, the General Disclosure Package and the Prospectus or (C)&nbsp;pursuant to the conversion
of convertible securities or exercise of options referred to in the Registration Statement, the General Disclosure Package and the Prospectus). The outstanding shares of capital stock of the Company have been duly authorized and are validly issued,
fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> None of the outstanding shares of capital stock of the Company was issued in violation of the preemptive or other similar rights of any securityholder of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiv)&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorization of Agreement</U>. This Agreement has been duly authorized, executed and delivered
by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xv)&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorization and Description of Securities</U>. The Securities to be
purchased by the Underwriters from the Company have been duly authorized for issuance and sale to the Underwriters pursuant to this Agreement and, when issued and delivered by the Company pursuant to this Agreement against payment of the
consideration set forth herein, will be validly issued and fully paid and <FONT STYLE="white-space:nowrap">non-assessable;</FONT> and the issuance of the Securities is not subject to the preemptive or other similar rights of any securityholder of
the Company. The Common Stock conforms in all material respects to all statements relating thereto contained in the Registration Statement, the General Disclosure Package and the Prospectus and such description conforms in all material respects to
the rights set forth in the instruments defining the same. No holder of Securities will be subject to personal liability solely by reason of being such a holder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvi)&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration Rights</U>. There are no persons with registration rights or other similar rights
to have any securities registered for sale pursuant to the Registration Statement or otherwise registered for sale or sold by the Company under the 1933 Act pursuant to this Agreement, other than those rights that have been disclosed in the
Registration Statement, the General Disclosure Package and the Prospectus and have been waived. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Absence of Violations, Defaults and Conflicts</U>. Neither the Company nor any Subsidiary is
(A)&nbsp;in violation of its charter, <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational document, (B)&nbsp;in default in the performance or observance of any obligation, agreement, covenant or condition contained in any
contract, indenture, mortgage, deed of trust, loan or credit agreement, note, lease or other agreement or instrument to which the Company or any Subsidiary is a party or by which either of them is bound or to which any of the properties or assets of
the Company or any Subsidiary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
is subject (collectively, &#147;<U>Agreements and Instruments</U>&#148;), except for such defaults that would not, singly or in the aggregate, result in a Material Adverse Effect, or (C)&nbsp;in
violation of any law, statute, rule, regulation, judgment, order, writ or decree of any arbitrator, court, governmental body, regulatory body, administrative agency or other authority, body or agency having jurisdiction over the Company or its
Subsidiaries or any of their respective properties, assets or operations (each, a &#147;<U>Governmental Entity</U>&#148;), except for such violations that would not, singly or in the aggregate, result in a Material Adverse Effect. The execution,
delivery and performance of this Agreement and the consummation of the transactions contemplated herein and in the Registration Statement, the General Disclosure Package and the Prospectus (including the issuance and sale of the Securities and the
use of the proceeds from the sale of the Securities as described therein under the caption &#147;<U>Use of Proceeds</U>&#148;) and compliance by the Company with its obligations hereunder have been duly authorized by all necessary corporate action
and do not and will not, whether with or without the giving of notice or passage of time or both, conflict with or constitute a breach of, or default or Repayment Event (as defined below) under, or result in the creation or imposition of any lien,
charge or encumbrance upon any properties or assets of the Company or its Subsidiaries pursuant to, the Agreements and Instruments (except for such conflicts, breaches, defaults or Repayment Events or liens, charges or encumbrances that would not,
singly or in the aggregate, result in a Material Adverse Effect), nor will such action result in any violation of the provisions of the charter, <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational document of the Company or its
Subsidiaries or any law, statute, rule, regulation, judgment, order, writ or decree of any Governmental Entity. As used herein, a &#147;<U>Repayment Event</U>&#148; means any event or condition which gives the holder of any note, debenture or other
evidence of indebtedness (or any person acting on such holder&#146;s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company or its Subsidiaries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xviii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Listing</U>. The Securities have been approved for listing on the Nasdaq Capital Market,
subject to notice of issuance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xix)&nbsp;&nbsp;&nbsp;&nbsp;<U>Absence of Labor Dispute</U>. No labor dispute with the
employees of the Company or its Subsidiaries exists or, to the knowledge of the Company, is imminent, and the Company is not aware of any existing or imminent labor disturbance by the employees of any of its or its Subsidiaries&#146; principal
suppliers, manufacturers, customers or contractors, which, in either case, would result in a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xx)&nbsp;&nbsp;&nbsp;&nbsp;<U>Absence of Proceedings</U>. Except as disclosed in the Registration Statement, the General
Disclosure Package and the Prospectus, there is no action, suit, proceeding, inquiry or, to the knowledge of the Company, investigation before or brought by any Governmental Entity (including, without limitation, any action, suit proceeding, inquiry
or investigation before or brought by the U.S. Food and Drug Administration (the &#147;<U>FDA</U>&#148;)) now pending or, to the knowledge of the Company, threatened, against or affecting the Company or its Subsidiaries, which would reasonably be
expected to result in a Material Adverse Effect, or which would reasonably be expected to materially and adversely affect their respective properties or assets or the consummation of the transactions contemplated in this Agreement or the performance
by the Company of its obligations hereunder; and the aggregate of all pending legal or governmental proceedings to which the Company or any such Subsidiary is a party or of which any of their respective properties or assets is the subject which are
not described in the Registration Statement, the General Disclosure Package and the Prospectus, including ordinary routine litigation incidental to the business, would not reasonably be expected to result in a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxi)&nbsp;&nbsp;&nbsp;&nbsp;<U>Accuracy of Exhibits</U>. There are no contracts or documents which are required to be
described in the Registration Statement, the General Disclosure Package or the Prospectus or to be filed as exhibits to the Registration Statement which have not been so described and filed as required. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Absence of Further Requirements</U>. No filing
with, or authorization, approval, consent, license, order, registration, qualification or decree of, any Governmental Entity is necessary or required for the performance by the Company of its obligations hereunder, in connection with the offering,
issuance or sale of the Securities hereunder or the consummation of the transactions contemplated by this Agreement, except such as have been already obtained or as may be required under the 1933 Act, the 1933 Act Regulations, the rules of the
Nasdaq Stock Market LLC, state securities laws or the rules of the Financial Industry Regulatory Authority, Inc. (&#147;<U>FINRA</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxiii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Possession of Licenses and Permits</U>. The Company and its Subsidiaries possess such
permits, licenses, approvals, consents and other authorizations (collectively, &#147;<U>Governmental Licenses</U>&#148;) issued by the appropriate Governmental Entities necessary to conduct the business now operated by them, except where the failure
so to possess would not, singly or in the aggregate, result in a Material Adverse Effect. The Company and its Subsidiaries are in compliance with the terms and conditions of all Governmental Licenses, except where the failure so to comply would not,
singly or in the aggregate, result in a Material Adverse Effect. All of the Governmental Licenses are valid and in full force and effect, except where the invalidity of such Governmental Licenses or the failure of such Governmental Licenses to be in
full force and effect would not, singly or in the aggregate, result in a Material Adverse Effect. Neither the Company nor its Subsidiaries have received any notice of proceedings relating to the revocation or modification of any Governmental
Licenses which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would result in a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxiv)&nbsp;&nbsp;&nbsp;&nbsp;<U>Title to Property</U>. The Company and its Subsidiaries have good and marketable title to all
real property owned by them and good title to all other properties owned by them, in each case, free and clear of all mortgages, pledges, liens, security interests, claims, restrictions or encumbrances of any kind except such as (A)&nbsp;are
described in the Registration Statement, the General Disclosure Package and the Prospectus or (B)&nbsp;do not, singly or in the aggregate, materially adversely affect the value of such property and do not materially adversely interfere with the use
made and proposed to be made of such property by the Company or its Subsidiaries; and all of the leases and subleases material to the business of the Company and its Subsidiaries, considered as one enterprise, and under which the Company or its
Subsidiaries holds properties described in the Registration Statement, the General Disclosure Package or the Prospectus, are in full force and effect, and neither the Company nor any such Subsidiary has any notice of any material claim of any sort
that has been asserted by anyone adverse to the rights of the Company or any Subsidiary under any of the leases or subleases mentioned above, or affecting or questioning the rights of the Company or such Subsidiary to the continued possession of the
leased or subleased premises under any such lease or sublease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxv)&nbsp;&nbsp;&nbsp;&nbsp;<U>Title to Intellectual
Property</U>. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, the Company owns or has valid, binding and enforceable licenses or other rights under the patents, patent applications, licenses,
inventions, copyrights, know how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks, trade names or other intellectual property necessary for,
or used in the conduct, or the proposed conduct, of the business of the Company in the manner described in the Registration Statement, the General Disclosure Package and the Prospectus (collectively, the &#147;<U>Intellectual Property</U>&#148;);
the patents, trademarks, and copyrights, if any, included within the Intellectual Property are valid, enforceable, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
and subsisting; other than as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, (A)&nbsp;the Company is not obligated to pay a material royalty, grant a
license to, or provide other material consideration to any third party in connection with the Intellectual Property, (B)&nbsp;the Company has not received any notice of any claim of infringement, misappropriation or conflict with any asserted rights
of others with respect to any of the Company&#146;s drug candidates, services, processes or Intellectual Property, (C)&nbsp;to the knowledge of the Company, neither the sale nor use of any of the discoveries, inventions, drug candidates, services or
processes of the Company referred to in the Registration Statement, the General Disclosure Package or the Prospectus do or will, to the knowledge of the Company, infringe, misappropriate or violate any right or valid patent claim of any third party,
(D)&nbsp;none of the technology employed by the Company has been obtained or is being used by the Company in material violation of any contractual obligation binding on the Company or, to the Company&#146;s knowledge, upon any of its officers,
directors or employees or otherwise in violation of the rights of any persons, (E)to the knowledge of the Company, no third party has any ownership right in or to any Intellectual Property that is owned by the Company, other than any <FONT
STYLE="white-space:nowrap">co-owner</FONT> of any patent constituting Intellectual Property who is listed on the records of the U.S. Patent and Trademark Office (the &#147;<U>USPTO</U>&#148;) and any <FONT STYLE="white-space:nowrap">co-owner</FONT>
of any patent application constituting Intellectual Property who is named in such patent application, and, to the knowledge of the Company, no third party has any ownership right in or to any Intellectual Property in any field of use that is
exclusively licensed to the Company, other than any licensor to the Company of such Intellectual Property, (F)&nbsp;to the knowledge of the Company, there is no material infringement by third parties of any Intellectual Property, (G)&nbsp;there is
no pending or, to the Company&#146;s knowledge, threatened action, suit, proceeding or claim by others challenging the Company&#146;s rights in or to any Intellectual Property, and (H)&nbsp;there is no pending or, to the Company&#146;s knowledge,
threatened action, suit, proceeding or claim by others challenging the validity or scope of any Intellectual Property. The Company is in compliance in all material respects with the terms of each agreement pursuant to which Intellectual Property has
been licensed to the Company, and all such agreements are in full force and effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxvi)&nbsp;&nbsp;&nbsp;&nbsp;<U>Patents and Patent Applications</U>. All patents and patent applications owned by or licensed
to the Company or under which the Company has rights have, to the knowledge of the Company, been duly and properly filed and maintained; to the knowledge of the Company, the parties prosecuting such patent applications have complied with their duty
of candor and disclosure to the USPTO in connection with such applications; and the Company is not aware of any facts required to be disclosed to the USPTO that were not disclosed to the USPTO and which would preclude the grant of a patent in
connection with any such application or would reasonably be expected to form the basis of a finding of invalidity with respect to any patents that have issued with respect to such applications. To the Company&#146;s knowledge, all patents and patent
applications owned by the Company and filed with the USPTO or any foreign or international patent authority (the &#147;<U>Company Patent Rights</U>&#148;) and all patents and patent applications <FONT STYLE="white-space:nowrap">in-licensed</FONT> by
the Company and filed with the USPTO or any foreign or international patent authority (the &#147;<U><FONT STYLE="white-space:nowrap">In-licensed</FONT> Patent Rights</U>&#148;) have been duly and properly filed; the Company believes it has complied
with its duty of candor and disclosure to the USPTO for the Company Patent Rights and, to the Company&#146;s knowledge, the licensors of the <FONT STYLE="white-space:nowrap">In-licensed</FONT> Patent Rights have complied with their duty of candor
and disclosure to the USPTO for the <FONT STYLE="white-space:nowrap">In-licensed</FONT> Patent Rights. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxvii)&nbsp;&nbsp;&nbsp;&nbsp;<U>FDA Compliance</U>. Except as described in the Registration Statement, the General Disclosure
Package and the Prospectus, the Company: (A)&nbsp;is and at all times has been in material compliance with all statutes, rules or regulations of the FDA and other comparable Governmental Entities applicable to the ownership, testing, development,
manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product under development, manufactured or distributed by the Company
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
(&#147;Applicable Laws&#148;); (B) has not received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence or written notice from the FDA or any
other Governmental Entity alleging or asserting material noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, exemptions, authorizations, permits and supplements or amendments thereto required by any such
Applicable Laws (&#147;Authorizations&#148;); (C) possesses all material Authorizations and such Authorizations are valid and in full force and effect and the Company is not in material violation of any term of any such Authorizations; (D)&nbsp;has
not received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA or any other Governmental Entity or third party alleging that any product operation or activity is in
material violation of any Applicable Laws or Authorizations and has no knowledge that the FDA or any other Governmental Entity or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding;
(E)&nbsp;has not received notice that the FDA or any other Governmental Entity has taken, is taking or intends to take action to limit, suspend, modify or revoke any material Authorizations and has no knowledge that the FDA or any other Governmental
Entity is considering such action; and (F)&nbsp;has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws
or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a
subsequent submission). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxviii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance with Health Care Laws</U>. The Company has operated
and currently is in compliance with all applicable health care laws, rules and regulations to the extent they apply to the Company and its current activities (except where such failure to operate or
<FONT STYLE="white-space:nowrap">non-compliance</FONT> would not, singly or in the aggregate, result in a Material Adverse Effect), including, without limitation, (i)&nbsp;the Federal, Food, Drug and Cosmetic Act (21 U.S.C. &#167;&#167; 301 et
seq.); (ii) all applicable federal, state, local and all applicable foreign healthcare related fraud and abuse laws, including, without limitation, the federal Anti-kickback Statute (42 U.S.C. &#167;
<FONT STYLE="white-space:nowrap">1320a-7b(b)),</FONT> the U.S. Physician Payments Sunshine Act (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7h),</FONT> the civil False Claims Act (31 U.S.C. &#167;&#167; 3729 et seq.), the criminal False
Claims Law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(a)),</FONT> all criminal laws relating to healthcare fraud and abuse, including but not limited to 18 U.S.C. Sections 286 and 287, the healthcare fraud criminal provisions under
the U.S. Health Insurance Portability and Accountability Act of 1996 (&#147;<U>HIPAA</U>&#148;) (42 U.S.C. Section&nbsp;1320d et seq.), the exclusion laws (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7),</FONT> and the civil monetary
penalties law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7a);</FONT> (iii) HIPAA, as amended by the Health Information Technology for Economic Clinical Health Act (42 U.S.C. Section&nbsp;17921 et seq.); (iv) the regulations promulgated
pursuant to such laws; and (v)&nbsp;any other similar local, state, federal, or foreign laws (collectively, the &#147;<U>Health Care Laws</U>&#148;).&nbsp;&nbsp;&nbsp;&nbsp;Neither the Company, nor to the Company&#146;s knowledge, any of its
officers, directors, employees or agents have engaged in activities which are, as applicable, cause for false claims liability, civil penalties, or mandatory or permissive exclusion from Medicare, Medicaid, or any other state or federal healthcare
program. The Company has not received written notice or other correspondence of any claim, action, suit, audit, survey, proceeding, hearing, enforcement, investigation, arbitration or other action (&#147;<U>Action</U>&#148;) from any court or
arbitrator or Governmental Entity or third party alleging that any product operation or activity is in violation of any Health Care Laws, and, to the Company&#146;s knowledge, no such claim, action, suit, proceeding, hearing, enforcement,
investigation, arbitration or other action is threatened. The Company is not a party to and does not have any ongoing reporting obligations pursuant to any corporate integrity agreement, deferred prosecution agreement, monitoring agreement, consent
decree, settlement order, plan of correction or similar agreement imposed by any Governmental Entity. Additionally, neither the Company, nor to the Company&#146;s knowledge, any of its employees, officers or directors, has been excluded,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
suspended or debarred from participation in any U.S. state or federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry,
investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxix)&nbsp;&nbsp;&nbsp;&nbsp;<U>Environmental Laws</U>. Except as described in the Registration Statement, the General
Disclosure Package and the Prospectus or would not, singly or in the aggregate, result in a Material Adverse Effect, (A)&nbsp;neither the Company nor any Subsidiary is in violation of any applicable federal, state, local or foreign statute, law,
rule, regulation, ordinance, code, policy or rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human
health, the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of
chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products, asbestos-containing materials or mold (collectively, &#147;<U>Hazardous Materials</U>&#148;) or to the manufacture, processing,
distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, &#147;<U>Environmental Laws</U>&#148;), (B) the Company and its Subsidiaries have all permits, authorizations and approvals required for
their operations under any applicable Environmental Laws and are each in compliance with their requirements, (C)&nbsp;there are no pending or, to the knowledge of the Company threatened, administrative, regulatory or judicial actions, suits,
demands, demand letters, claims, liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company or any Subsidiary and (D)&nbsp;to the Company&#146;s knowledge, there are no events or
circumstances that would reasonably be expected to form the basis of an order for <FONT STYLE="white-space:nowrap">clean-up</FONT> or remediation, or an action, suit or proceeding by any private party or Governmental Entity, against or affecting the
Company or any Subsidiary relating to Hazardous Materials or any Environmental Laws.<U>Accounting Controls and Disclosure Controls</U>. The Company maintains a system of &#147;internal control over financial reporting&#148; (as such term is defined
in Rule <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> of the 1934 Regulations) that complies with the requirements of the Exchange Act and has been designed by its respective principal executive and principal financial officers, or under their
supervision and are sufficient to provide reasonable assurances that (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorization; (ii)&nbsp;transactions are recorded as necessary to permit preparation of
financial statements in conformity with GAAP and to maintain accountability for assets; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization; (iv)&nbsp;the recorded accountability for
assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences and (v)&nbsp;the interactive data in eXtensible Business Reporting Language incorporated by reference in the Registration
Statement, the General Disclosure Package and the Prospectus fairly presents the information called for in all material respects and is prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. Except as described in
the Registration Statement, the General Disclosure Package and the Prospectus, since the end of the Company&#146;s most recent audited fiscal year, there has been (A)&nbsp;no material weakness in the Company&#146;s internal control over financial
reporting (whether or not remediated) and (B)&nbsp;no change in the Company&#146;s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over
financial reporting. The Company has no reason to believe that it does not comply with Section&nbsp;215.02 of the Commission&#146;s Compliance and Disclosure Interpretations of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> regarding a <FONT
STYLE="white-space:nowrap">one-year</FONT> transition under Item 308(a) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> with respect to its annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ending
December&nbsp;31, 2017 and the Company expects to avail itself of such relief. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxx)&nbsp;&nbsp;&nbsp;&nbsp;<U>Nonclinical Studies and Clinical Trials</U>. The
nonclinical studies and clinical trials conducted by or, to the Company&#146;s knowledge, on behalf of the Company were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and
controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder (collectively,
&#147;FFDCA&#148;); the descriptions of the results of such nonclinical studies and clinical trials contained in the Registration Statement, the General Disclosure Package and the Prospectus are, to the Company&#146;s knowledge, accurate and
complete in all material respects and fairly present the data derived from such nonclinical studies and clinical trials; except to the extent disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company is
not aware of any nonclinical studies or clinical trials, the results of which the Company believes reasonably call into question any study or trial results described or referred to in the Registration Statement, the General Disclosure Package and
the Prospectus when viewed in the context in which such results are described; and, except to the extent disclosed in the Registration Statement, the General Disclosure Package or the Prospectus, the Company has not received any written notices or
other correspondence from the FDA or any other Governmental Entity requiring the termination or suspension of any studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to
modifications in connection with the design and implementation of such studies or trials, copies of which communications have been made available to you.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxi)&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment of Taxes</U>. All United States federal income tax returns of the Company and its
Subsidiaries required by law to be filed have been filed and all taxes shown by such returns or otherwise assessed, which are due and payable, have been paid, except assessments against which appeals have been or will be promptly taken and as to
which adequate reserves have been provided in conformity with GAAP. The United States federal income tax returns of the Company through the fiscal year ended December&nbsp;31, 2016 have been settled and no assessment in connection therewith has been
made against the Company. The Company and its Subsidiaries have filed all other tax returns that are required to have been filed by them pursuant to applicable foreign, state, local or other law except insofar as the failure to file such returns
would not result in a Material Adverse Effect, and have paid all taxes due pursuant to such returns or pursuant to any assessment received by the Company and its Subsidiaries, except for such taxes, if any, as are being contested in good faith and
as to which adequate reserves have been established by the Company. The charges, accruals and reserves on the books of the Company in respect of any income and corporation tax liability for any years not finally determined are, in conformity with
GAAP, adequate to meet any assessments or <FONT STYLE="white-space:nowrap">re-assessments</FONT> for additional income tax for any years not finally determined, except to the extent of any inadequacy that would not result in a Material Adverse
Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance</U>. The Company and its Subsidiaries carry or are entitled to the
benefits of insurance, with financially sound and reputable insurers, in such amounts and covering such risks as is generally maintained by companies of established repute and comparable size engaged in the same or similar business, and all such
insurance is in full force and effect. The Company has no reason to believe that it or its Subsidiaries will not be able (A)&nbsp;to renew its existing insurance coverage as and when such policies expire or (B)&nbsp;to obtain comparable coverage
from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not result in a Material Adverse Effect. Neither of the Company nor its Subsidiaries has been denied any insurance
coverage which it has sought or for which it has applied. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxiii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Investment Company Act</U>. The Company is not
required, and upon the issuance and sale of the Securities as herein contemplated and the application of the net proceeds therefrom as described in the Registration Statement, the General Disclosure Package and the Prospectus will not be required,
to register as an &#147;investment company&#148; under the Investment Company Act of 1940, as amended (the &#147;<U>1940 Act</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxiv)&nbsp;&nbsp;&nbsp;&nbsp;<U>Absence of Manipulation</U>. Neither the Company nor, to the knowledge of the Company, any
affiliate of the Company has taken, nor will the Company or any affiliate take, directly or indirectly, any action which is designed, or would reasonably be expected, to cause or result in, or which constitutes, the stabilization or manipulation of
the price of any security of the Company to facilitate the sale or resale of the Securities or to result in a violation of Regulation M under the 1934 Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxv)&nbsp;&nbsp;&nbsp;&nbsp;<U>Foreign Corrupt Practices Act</U>. None of the Company, its Subsidiaries or, to the knowledge
of the Company, any director, officer, agent, employee, affiliate or other person acting on behalf of the Company or its Subsidiaries is aware of or has taken any action, directly or indirectly, that would result in a violation by such persons of
the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the &#147;<U>FCPA</U>&#148;), including, without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in
furtherance of an offer, payment, promise to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any &#147;foreign official&#148; (as such term is defined
in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, in contravention of the FCPA and the Company has and, to the knowledge of the Company, its affiliates have conducted their businesses in
compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxvi)&nbsp;&nbsp;&nbsp;&nbsp; <U>Money Laundering Laws</U>. The operations of the Company and its Subsidiaries are and have
been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable jurisdictions,
the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the &#147;<U>Money Laundering Laws</U>&#148;); and no action, suit or
proceeding by or before any Governmental Entity involving the Company or its Subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxvii)&nbsp;&nbsp;&nbsp;&nbsp;<U>OFAC</U>. None of the Company, its Subsidiaries or, to the knowledge of the Company, any
director, officer, agent, employee, affiliate or representative of the Company or its Subsidiaries is an individual or entity (&#147;<U>Person</U>&#148;) currently the subject or target of any sanctions administered or enforced by the United States
Government, including, without limitation, the U.S. Department of the Treasury&#146;s Office of Foreign Assets Control, the United Nations Security Council, the European Union, Her Majesty&#146;s Treasury, or other relevant sanctions authority
(collectively, &#147;<U>Sanctions</U>&#148;), nor is the Company located, organized or resident in a country or territory that is the subject of Sanctions; and the Company will not directly or indirectly use the proceeds of the sale of the
Securities, or lend, contribute or otherwise make available such proceeds to any Subsidiary, joint venture partners or other Person, to fund any activities of or business with any Person, or in any country or territory, that, at the time of such
funding, is the subject of Sanctions or in any other manner that will result in a violation by any Person (including any Person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxviii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Lending Relationship</U><I>. </I>Except as
disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company (i)&nbsp;does not have any&nbsp;material lending or other relationship with any banking or lending affiliate of any Underwriter and
(ii)&nbsp;does not intend to use any of the proceeds from the sale of the Securities to repay any outstanding debt owed to any affiliate of any Underwriter. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxix)&nbsp;&nbsp;&nbsp;&nbsp; <U>Statistical and Market-Related Data</U>. Any statistical and market-related data included in
the Registration Statement, the General Disclosure Package or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate in all material respects and, to the extent required,
the Company has obtained the written consent to the use of such data from such sources. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xl)&nbsp;&nbsp;&nbsp;&nbsp;<U>Maintenance of Rating</U>. The Company has no debt securities or preferred stock that is rated
by any &#147;nationally recognized statistical rating organization&#148; (as that term is defined by the Commission for purposes of Rule 436(g)(2) under the 1933 Act). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xli)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Broker Fees</U>. Except as disclosed in the General Disclosure Package, there are no
contracts, agreements or understandings between the Company and any person that would give rise to a valid claim against the Company or any Underwriter for a brokerage commission, finder&#146;s fee or other like payment in connection with the
offering of the Securities contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Officer&#146;s Certificates</I>. Any certificate signed by
any officer of the Company or any of its Subsidiaries delivered to the Representatives or to counsel for the Underwriters pursuant to the provisions hereof shall be deemed a representation and warranty by the Company to each Underwriter as to the
matters covered thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Sale and Delivery to Underwriters; Closing</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Initial Securities</I>. On the basis of the representations and warranties herein contained and subject to the
terms and conditions herein set forth, the Company agrees to sell to each Underwriter, severally and not jointly, and each Underwriter, severally and not jointly, agrees to purchase from the Company, at the price per share set forth in
<U>Schedule</U><U></U><U>&nbsp;A</U>, that number of Initial Securities set forth in <U>Schedule</U><U></U><U>&nbsp;A</U> opposite the name of such Underwriter, plus any additional number of Initial Securities which such Underwriter may become
obligated to purchase pursuant to the provisions of Section&nbsp;10 hereof, subject, in each case, to such adjustments among the Underwriters as the Representatives in their sole discretion shall make to eliminate any sales or purchases of
fractional shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Option Securities</I>. In addition, on the basis of the representations and warranties
herein contained and subject to the terms and conditions herein set forth, the Company hereby grants an option to the Underwriters, severally and not jointly, to purchase up to an additional 769,500 shares of Common Stock, at the price per share set
forth in <U>Schedule</U><U></U><U>&nbsp;A</U>, less an amount per share equal to any dividends or distributions declared by the Company and payable on the Initial Securities but not payable on the Option Securities. The option hereby granted may be
exercised for 30&nbsp;days after the date hereof and may be exercised in whole or in part at any time from time to time upon notice by the Representatives to the Company setting forth the number of Option Securities as to which the several
Underwriters are then exercising the option and the time and date of payment and delivery for such Option Securities. Any such time and date of delivery (a &#147;<U>Date of Delivery</U>&#148;) shall be determined by the Representatives, but any Date
of Delivery after the Closing Time shall not be later than seven full business days nor earlier than two full </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
business days after the exercise of said option, nor in any event prior to the Closing Time. If the option is exercised as to all or any portion of the Option Securities, each of the
Underwriters, acting severally and not jointly, will purchase that proportion of the total number of Option Securities then being purchased which the number of Initial Securities set forth in <U>Schedule A</U> opposite the name of such Underwriter
bears to the total number of Initial Securities, subject, in each case, to such adjustments as the Representatives in their sole discretion shall make to eliminate any sales or purchases of fractional shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>Payment</I>. Payment of the purchase price for, and delivery of certificates or security entitlements for, the
Initial Securities shall be made at the offices of Goodwin Procter LLP, The New York Times Building, 620 Eighth Avenue, New York, NY 10018, or at such other place as shall be agreed upon by the Representatives and the Company, at 10:00&nbsp;A.M.
(New York City time) on the second (third, if the pricing occurs after 4:30 P.M. (New York City time) on any given day) business day after the date hereof (unless postponed in accordance with the provisions of Section&nbsp;10), or such other time
not later than ten business days after such date as shall be agreed upon by the Representatives and the Company (such time and date of payment and delivery being herein called &#147;<U>Closing Time</U>&#148;). Delivery of the Initial Securities at
the Closing Time shall be made through the facilities of The Depository Trust Company unless the Representatives shall otherwise instruct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the event that any or all of the Option Securities are purchased by the Underwriters, payment of the purchase price for, and
delivery of certificates or security entitlements for, such Option Securities shall be made at the <FONT STYLE="white-space:nowrap">above-mentioned</FONT> offices, or at such other place as shall be agreed upon by the Representatives and the
Company, on each Date of Delivery as specified in the notice from the Representatives to the Company. Delivery of the Option Securities on each such Date of Delivery shall be made through the facilities of The Depository Trust Company unless the
Representatives shall otherwise instruct. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment shall be made to the Company by wire transfer of immediately available funds to a bank
account designated by the Company, against delivery to the Representatives for the respective accounts of the Underwriters of certificates or security entitlements for the Securities to be purchased by them. It is understood that each Underwriter
has authorized the Representatives, for their accounts, to accept delivery of, receipt for, and make payment of the purchase price for, the Initial Securities and the Option Securities, if any, which it has agreed to purchase. Leerink and Piper
Jaffray, individually and not as representatives of the Underwriters, may (but shall not be obligated to) make payment of the purchase price for the Initial Securities or the Option Securities, if any, to be purchased by any Underwriter whose funds
have not been received by the Closing Time or the relevant Date of Delivery, as the case may be, but such payment shall not relieve such Underwriter from its obligations hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Covenants of the Company</U>. The Company covenants with each Underwriter as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Compliance with Securities Regulations and Commission Requests</I>. The Company, subject to Section&nbsp;3(b),
will comply with the requirements of Rule 430B, and will notify the Representatives as soon as practicable, and confirm the notice in writing, (i)&nbsp;when any post-effective amendment to the Registration Statement shall become effective or any
amendment or supplement to the Prospectus shall have been filed, (ii)&nbsp;of the receipt of any comments from the Commission, (iii)&nbsp;of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement
to the Prospectus (including any document incorporated by reference therein) or for additional information, (iv)&nbsp;of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any
post-effective amendment or of any order preventing or suspending the use of any preliminary prospectus or the Prospectus, or of the suspension of the qualification of the Securities for offering or sale in any jurisdiction, or of the initiation or
threatening of any proceedings for any of such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purposes or of any examination pursuant to Section&nbsp;8(d) or 8(e) of the 1933 Act concerning the Registration Statement and (v)&nbsp;if the Company becomes the subject of a proceeding under
Section&nbsp;8A of the 1933 Act in connection with the offering of the Securities. The Company will effect all filings required under Rule 424(b), in the manner and within the time period required by Rule 424(b) (without reliance on Rule 424(b)(8)),
and will take such steps as it deems necessary to ascertain promptly whether the form of prospectus transmitted for filing under Rule 424(b) was received for filing by the Commission and, in the event that it was not, it will promptly file such
prospectus. The Company will make every reasonable effort to prevent the issuance of any stop order, prevention or suspension and, if any such order is issued, to obtain the lifting thereof at the earliest possible moment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Continued Compliance with Securities Laws</I>. The Company will comply with the 1933 Act, the 1933 Act
Regulations, the 1934 Act and the 1934 Act Regulations so as to permit the completion of the distribution of the Securities as contemplated in this Agreement and in the Registration Statement, the General Disclosure Package and the Prospectus. If at
any time when a prospectus relating to the Securities is (or, but for the exception afforded by Rule 172 of the 1933 Act Regulations (&#147;<U>Rule 172</U>&#148;), would be) required by the 1933 Act to be delivered in connection with sales of the
Securities, any event shall occur or condition shall exist as a result of which it is necessary, in the opinion of counsel for the Underwriters or for the Company, to (i)&nbsp;amend the Registration Statement in order that the Registration Statement
will not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, (ii)&nbsp;amend or supplement the General Disclosure Package or the
Prospectus in order that the General Disclosure Package or the Prospectus, as the case may be, will not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein not misleading
in the light of the circumstances existing at the time it is delivered to a purchaser or (iii)&nbsp;amend the Registration Statement or amend or supplement the General Disclosure Package or the Prospectus, as the case may be, in order to comply with
the requirements of the 1933 Act or the 1933 Act Regulations, the Company will promptly (A)&nbsp;give the Representatives notice of such event, (B)&nbsp;prepare any amendment or supplement as may be necessary to correct such statement or omission or
to make the Registration Statement, the General Disclosure Package or the Prospectus comply with such requirements and, a reasonable amount of time prior to any proposed filing or use, furnish the Representatives with copies of any such amendment or
supplement and (C)&nbsp;file with the Commission any such amendment or supplement; provided that the Company shall not file or use any such amendment or supplement to which the Representatives or counsel for the Underwriters shall reasonably object.
The Company will furnish to the Underwriters such number of copies of such amendment or supplement as the Underwriters may reasonably request. The Company has given the Representatives notice of any filings made pursuant to the 1934 Act or the 1934
Act Regulations within 48 hours prior to the Applicable Time; the Company will give the Representatives notice of its intention to make any such filing from the Applicable Time to the Closing Time and will furnish the Representatives with copies of
any such documents a reasonable amount of time prior to such proposed filing, as the case may be, and will not file or use any such document to which the Representatives or counsel for the Underwriters shall reasonably object. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>Delivery of Registration Statement</I>. The Company has furnished or will deliver to the Representatives and
counsel for the Underwriters, without charge, signed copies of the Registration Statement as originally filed and each amendment thereto (including exhibits filed therewith or incorporated by reference therein and documents incorporated or deemed
incorporated by reference therein) and signed copies of all consents and certificates of experts, and will also deliver to the Representatives, without charge, a conformed copy of the Registration Statement as originally filed and each amendment
thereto (without exhibits) for each of the Underwriters. The copies of the Registration Statement and each amendment thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission
pursuant to EDGAR, except to the extent permitted by Regulation <FONT STYLE="white-space:nowrap">S-T.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<I>Delivery of Prospectuses</I>. The Company has delivered to each
Underwriter, without charge, as many copies of each preliminary prospectus as such Underwriter reasonably requested, and the Company hereby consents to the use of such copies for purposes permitted by the 1933 Act. The Company will furnish to each
Underwriter, without charge, during the period when a prospectus relating to the Securities is (or, but for the exception afforded by Rule 172, would be) required to be delivered under the 1933 Act, such number of copies of the Prospectus (as
amended or supplemented) as such Underwriter may reasonably request. The Prospectus and any amendments or supplements thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission
pursuant to EDGAR, except to the extent permitted by Regulation <FONT STYLE="white-space:nowrap">S-T.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<I>Blue Sky Qualifications</I>. The Company will use its reasonable best efforts, in cooperation with the
Underwriters, to qualify the Securities for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as the Representatives may reasonably designate and to maintain such qualifications in
effect so long as required to complete the distribution of the Securities; provided, however, that the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a dealer in
securities in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<I>Rule 158</I>. The Company will timely file such reports pursuant to the 1934 Act as are necessary in order to
make generally available to its securityholders as soon as practicable an earning statement for the purposes of, and to provide to the Underwriters the benefits contemplated by, the last paragraph of Section&nbsp;11(a) of the 1933 Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<I>Use of Proceeds</I>. The Company will use the net proceeds received by it from the sale of the Securities in all
material respects in the manner specified in the Registration Statement, the General Disclosure Package and the Prospectus under the heading &#147;Use of Proceeds.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<I>Listing</I>. The Company will use its reasonable best efforts to effect and maintain the listing of the Common
Stock (including the Securities) on the Nasdaq Capital Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<I>Restriction on Sale of Securities</I>.
During a period of 90 days from the date of the Prospectus, the Company will not, without the prior written consent of the Representatives, (i)&nbsp;directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to
purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock or
file any registration statement under the 1933 Act with respect to any of the foregoing, (ii)&nbsp;enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of
ownership of the Common Stock, whether any such swap or transaction described in clause (i)&nbsp;or (ii) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise or (iii)&nbsp;publicly announce an intention
to effect any such swap, agreement or other transaction described in clauses (i)&nbsp;and (ii). The foregoing sentence shall not apply to (A)&nbsp;the Securities to be sold hereunder; (B)&nbsp;any shares of Common Stock issued by the Company upon
the exercise of an option or warrant or the conversion of a convertible security outstanding on the date hereof and referred to in the Registration Statement, the General Disclosure Package and the Prospectus; (C)&nbsp;any shares of Common Stock
issued or options to purchase Common Stock granted pursuant to existing employee benefit plans of the Company referred to in the Registration Statement, the General Disclosure Package and the Prospectus; (D)&nbsp;any shares of Common Stock issued
pursuant to any existing <FONT STYLE="white-space:nowrap">non-employee</FONT> director stock plan or dividend reinvestment plan referred to in the Registration Statement, the General Disclosure Package and the Prospectus; (E)&nbsp;the filing by the
Company of any registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> or a successor form thereto; or (F)&nbsp;issuances of Common Stock or securities exercisable for, convertible into or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exchangeable for Common Stock in connection with any acquisition, collaboration, merger, licensing or other joint venture or strategic transaction involving the Company; provided that in the case
of clause (F), that such issuances shall not be greater than 7% of the total outstanding shares of the Company immediately following the initial closing hereunder and the recipients of such shares of Common Stock agree to be bound by a lockup letter
in the form executed by directors, officers and certain stockholders pursuant to Section&nbsp;5(i) hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;<I>Reporting Requirements</I>. The Company, during the period when a Prospectus relating to the Securities is (or,
but for the exception afforded by Rule 172, would be) required to be delivered under the 1933 Act, will file all documents required to be filed with the Commission pursuant to the 1934 Act within the time periods required by the 1934 Act and 1934
Act Regulations. Additionally, the Company shall report the use of proceeds from the issuance of the Securities as may be required under Rule 463 under the 1933 Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;<I>Issuer Free Writing Prospectuses</I>. The Company agrees that, unless it obtains the prior written consent of
the Representatives, it will not make any offer relating to the Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a &#147;free writing prospectus,&#148; or a portion thereof, required to be filed
by the Company with the Commission or retained by the Company under Rule 433; provided that the Representatives will be deemed to have consented to the Issuer Free Writing Prospectuses listed on <U>Schedule</U><U></U><U><FONT
STYLE="white-space:nowrap">&nbsp;B-2</FONT></U> hereto and any &#147;road show that is a written communication&#148; within the meaning of Rule 433(d)(8)(i) that has been reviewed by the Representatives. The Company represents that it has treated or
agrees that it will treat each such free writing prospectus consented to, or deemed consented to, by the Representatives as an &#147;issuer free writing prospectus,&#148; as defined in Rule 433, and that it has complied and will comply with the
applicable requirements of Rule 433 with respect thereto, including timely filing with the Commission where required, legending and record keeping. If at any time following issuance of an Issuer Free Writing Prospectus there occurred or occurs an
event or development as a result of which such Issuer Free Writing Prospectus conflicted or would conflict with the information contained in the Registration Statement, any preliminary prospectus or the Prospectus or included or would include an
untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly
notify the Representatives and will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;<I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Materials</I>. If at any time following the distribution of any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication there occurred or occurs an event or development as a result of
which such Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material fact
necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representatives and will promptly amend or supplement, at its own expense,
such Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication to eliminate or correct such untrue statement or omission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;<I>Emerging Growth Company Status</I>. The Company will promptly notify the Representatives if the Company ceases
to be an Emerging Growth Company at any time prior to the later of (i)&nbsp;completion of the distribution of the Securities within the meaning of the 1933 Act and (ii)&nbsp;completion of the <FONT STYLE="white-space:nowrap">90-day</FONT> restricted
period referred to in Section&nbsp;3(i). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment of Expenses</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Expenses</I>. The Company will pay or cause to be paid all expenses incident to the performance of its
obligations under this Agreement, including (i)&nbsp;the preparation, printing and filing of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Registration Statement (including financial statements and exhibits) as originally filed and each amendment thereto, (ii)&nbsp;the preparation, printing and delivery to the Underwriters of copies
of each preliminary prospectus, each Issuer Free Writing Prospectus and the Prospectus and any amendments or supplements thereto and any costs associated with electronic delivery of any of the foregoing by the Underwriters to investors,
(iii)&nbsp;the preparation, issuance and delivery of the certificates or security entitlements for the Securities to the Underwriters, including any stock or other transfer taxes and any stamp or other duties payable upon the sale, issuance or
delivery of the Securities to the Underwriters, (iv)&nbsp;the fees and disbursements of the Company&#146;s counsel, accountants and other advisors, (v)&nbsp;the qualification of the Securities under securities laws in accordance with the provisions
of Section&nbsp;3(e) hereof, including filing fees and the reasonable fees and disbursements of counsel for the Underwriters in connection therewith and in connection with the preparation of a &#147;Blue Sky Survey&#148; and any supplement thereto,
(vi)&nbsp;the fees and expenses of any transfer agent or registrar for the Securities, (vii)&nbsp;the costs and expenses of the Company relating to investor presentations on any &#147;road show&#148; undertaken in connection with the marketing of
the Securities, including without limitation, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations, travel and lodging expenses of the
representatives and officers of the Company and any such consultants, and the cost of aircraft and other transportation chartered in connection with the road show, (viii)&nbsp;the filing fees incident to, and the reasonable fees and disbursements of
counsel to the Underwriters in connection with, the review by FINRA of the terms of the sale of the Securities, (ix)&nbsp;the fees and expenses incurred in connection with the listing of the Securities on the Nasdaq Capital Market, and (x)&nbsp;the
costs and expenses (including, without limitation, any damages or other amounts payable in connection with legal or contractual liability) associated with the reforming of any contracts for sale of the Securities made by the Underwriters caused by a
breach of the representation contained in the third sentence of Section&nbsp;1(a)(ii); provided, however, that the fees and disbursements of counsel for the Underwriters contemplated by clauses (v)&nbsp;and (viii) above shall not exceed $25,000, in
the aggregate. Except as provided in this Section&nbsp;4, Section&nbsp;6 or Section&nbsp;7, the Underwriters shall pay their own expenses, including the fees and disbursements of their counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Termination of Agreement</I>. If this Agreement is terminated by the Representatives in accordance with the
provisions of Section&nbsp;5, Section&nbsp;9(a)(i), Section&nbsp;9(a)(iii) or Section&nbsp;10 hereof, the Company shall reimburse the Underwriters for all of their reasonably documented
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, including the reasonable fees and disbursements of counsel for the Underwriters; provided, however, that if this Agreement is terminated by the
Representatives pursuant to Section&nbsp;10 hereof, the Company shall have no obligation to reimburse any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses of any Underwriter that has failed to
purchase the Securities that such Underwriter has agreed to purchase hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Conditions of
Underwriters&#146; Obligations</U>. The obligations of the several Underwriters hereunder are subject to the accuracy of the representations and warranties of the Company contained herein or in certificates of any officer of the Company or any of
its Subsidiaries delivered pursuant to the provisions hereof, to the performance by the Company of its covenants and other obligations hereunder, and to the following further conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Effectiveness of Registration Statement</I>. The Registration Statement, including any Rule 462(b) Registration
Statement, has become effective and, at the Closing Time, no stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto has been issued under the 1933 Act, no order preventing or suspending the use
of any preliminary prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or, to the Company&#146;s knowledge, contemplated; and the Company has complied with each request (if
any) from the Commission for additional information to the reasonable satisfaction of counsel to the Underwriters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Opinion of Counsel for Company</I>. At the Closing Time, the
Representatives shall have received the opinion and the negative assurance letter, each dated the Closing Time, of Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo P.C., counsel for the Company, together with the opinion of McCarter&nbsp;&amp;
English, LLP, special counsel for the Company with respect to intellectual property matters, each in form and substance reasonably satisfactory to counsel for the Underwriters, together with signed or reproduced copies of each such letter for each
of the other Underwriters. In giving such opinions such counsel may rely, as to all matters governed by the laws of jurisdictions other than the law of the State of New York, the General Corporation Law of the State of Delaware and the federal
securities laws of the United States, upon the opinions of counsel reasonably satisfactory to the Representatives. Such counsel may also state that, insofar as such opinion involves factual matters, they have relied, to the extent they deem proper,
upon certificates of officers and other representatives of the Company and its Subsidiaries and certificates of public officials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>Opinion of Counsel for Underwriters</I>. At the Closing Time, the Representatives shall have received the
opinion, and negative assurance letter, each dated the Closing Time, of Goodwin Procter LLP, counsel for the Underwriters, together with signed or reproduced copies of such letters for each of the other Underwriters in form and substance
satisfactory to the Representatives. In giving such opinion such counsel may rely, as to all matters governed by the laws of jurisdictions other than the law of the State of New York, the General Corporation Law of the State of Delaware and the
federal securities laws of the United States, upon the opinions of counsel reasonably satisfactory to the Representatives. Such counsel may also state that, insofar as such opinion involves factual matters, they have relied, to the extent they deem
proper, upon certificates of officers and other representatives of the Company and its Subsidiaries and certificates of public officials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<I>Officers&#146; Certificate</I>. At the Closing Time, there shall not have been, since the date hereof or since
the respective dates as of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus, any material adverse change in the condition, financial or otherwise, or in the earnings, business affairs or
business prospects of the Company and its Subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business, and the Representatives shall have received a certificate of the principal executive officer of the
Company and of the principal financial officer of the Company, dated the Closing Time, to the effect that (i)&nbsp;there has been no such material adverse change, (ii)&nbsp;the representations and warranties of the Company in this Agreement are true
and correct with the same force and effect as though expressly made at and as of the Closing Time, (iii)&nbsp;the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied at or prior to the
Closing Time, and (iv)&nbsp;no stop order suspending the effectiveness of the Registration Statement under the 1933 Act has been issued, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been issued and no
proceedings for any of those purposes have been instituted or are pending or, to their knowledge, contemplated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<I>Accountant&#146;s Comfort Letters</I>. At the time of the execution of this Agreement, the Representatives shall
have received from each of KPMG US LLP and Ernst&nbsp;&amp; Young LLP a letter, dated such date, in form and substance satisfactory to the Representatives, together with signed or reproduced copies of such letter for each of the other Underwriters
containing statements and information of the type ordinarily included in accountants&#146; &#147;comfort letters&#148; to underwriters with respect to the financial statements and certain financial information contained in the Registration
Statement, the General Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<I>Bring-down Comfort Letters</I>. At the
Closing Time, the Representatives shall have received from each of KPMG US LLP and Ernst&nbsp;&amp; Young LLP a letter, dated as of the Closing Time, to the effect that they reaffirm the statements made in the letter furnished pursuant to subsection
(e)&nbsp;of this Section, except that the specified date referred to shall be a date not more than three business days prior to the Closing Time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<I>Chief Financial Officer Certificate</I>. At the time of the
execution of this Agreement and at the Closing Time, the Representatives shall have received from the Chief Financial Officer of the Company, a certificate in form and substance satisfactory to the Representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<I>Approval of Listing</I>. At the Closing Time, the Securities shall have been approved for listing on the Nasdaq
Capital Market, subject only to official notice of issuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Objection</I>. FINRA has confirmed that it
has not raised any objection with respect to the fairness and reasonableness of the underwriting terms and arrangements relating to the offering of the Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;<I><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements</I>. At the date of this Agreement, the
Representatives shall have received an agreement substantially in the form of <U>Exhibit</U><U></U><U>&nbsp;A</U> hereto signed by the individuals or entities, as the case may be, set forth on <U>Schedule D</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;<I>Conditions to Purchase of Option Securities</I>. In the event that the Underwriters exercise their option
provided in Section&nbsp;2(b) hereof to purchase all or any portion of the Option Securities, the representations and warranties of the Company contained herein and the statements in any certificates furnished by the Company and any of its
Subsidiaries hereunder shall be true and correct as of each Date of Delivery and, at the relevant Date of Delivery, the Representatives shall have received: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Officers&#146; Certificate</U>. A certificate, dated such Date of Delivery, of the principal
executive officer of the Company and of the principal financial officer of the Company confirming that the certificate delivered at the Closing Time pursuant to Section&nbsp;5(d) hereof remains true and correct as of such Date of Delivery. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Opinion of Counsel for Company</U>. If requested by the Representatives, the opinion, and
negative assurance letter, of Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo P.C., counsel for the Company, together with the opinion of McCarter&nbsp;&amp; English, LLP, special counsel for the Company with respect to intellectual property matters,
each in form and substance reasonably satisfactory to counsel for the Underwriters, dated such Date of Delivery, relating to the Option Securities to be purchased on such Date of Delivery and otherwise to the same effect as the opinions and negative
assurance letter required by Section&nbsp;5(b) hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Opinion of Counsel for
Underwriters</U>. If requested by the Representatives, the opinion, and negative assurance letter, of Goodwin Procter LLP counsel for the Underwriters, dated such Date of Delivery, relating to the Option Securities to be purchased on such Date of
Delivery and otherwise to the same effect as the opinion and negative assurance letter required by Section&nbsp;5(c) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;<U>Bring-down Comfort Letter</U>. If requested by the Representatives, a letter from each of KPMG
US LLP and Ernst&nbsp;&amp; Young LLP, in form and substance reasonably satisfactory to the Representatives and dated such Date of Delivery, substantially in the same form and substance as the letter furnished to the Representatives pursuant to
subsection (f)&nbsp;of this Section, except that the &#147;specified date&#148; in the letter furnished pursuant to this paragraph shall be a date not more than three business days prior to such Date of Delivery. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;<I>Additional Documents</I>. At the Closing Time and at each Date of
Delivery (if any), counsel for the Underwriters shall have been furnished with such documents and opinions as they may reasonably require for the purpose of enabling them to pass upon the issuance and sale of the Securities as herein contemplated,
or in order to evidence the accuracy of any of the representations or warranties, or the fulfillment of any of the conditions, herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Securities as
herein contemplated shall be reasonably satisfactory in form and substance to the Representatives and counsel for the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;<I>Termination of Agreement</I>. If any condition specified in this Section shall not have been fulfilled when and
as required to be fulfilled, this Agreement, or, in the case of any condition to the purchase of Option Securities on a Date of Delivery which is after the Closing Time, the obligations of the several Underwriters to purchase the relevant Option
Securities, may be terminated by the Representatives by notice to the Company at any time at or prior to Closing Time or such Date of Delivery, as the case may be, and such termination shall be without liability of any party to any other party
except as provided in Section&nbsp;4 and except that Sections 1, 4, 6, 7, 8, 14, 15 and 16 shall survive any such termination and remain in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Indemnification of Underwriters</I>. The Company agrees to indemnify and hold harmless each Underwriter, its
affiliates (as such term is defined in Rule 501(b) under the 1933 Act (each, an &#147;<U>Affiliate</U>&#148;)), its selling agents and each person, if any, who controls any Underwriter within the meaning of Section&nbsp;15 of the 1933 Act or
Section&nbsp;20 of the 1934 Act as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;against any and all loss, liability, claim, damage
and expense whatsoever, as incurred, arising out of any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment thereto), including any information deemed to be a part thereof
pursuant to Rule 430B, or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading or arising out of any untrue statement or alleged untrue statement of a
material fact included (A)&nbsp;in any preliminary prospectus, any Issuer Free Writing Prospectus, any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, the General Disclosure
Package or the Prospectus (or any amendment or supplement thereto), or (B)&nbsp;in any materials or information provided to investors by, or with the approval of, the Company in connection with the marketing of the offering of the Securities
(&#147;<U>Marketing Materials</U>&#148;), including any roadshow or investor presentations made to investors by the Company (whether in person or electronically), or the omission or alleged omission in any preliminary prospectus, any Issuer Free
Writing Prospectus, any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, the General Disclosure Package, the Prospectus (or any amendment or supplement thereto) or in any
Marketing Materials of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;against any and all loss, liability, claim, damage and expense whatsoever, as incurred, to the
extent of the aggregate amount paid in settlement of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or of any claim whatsoever based upon any such untrue statement or omission, or any
such alleged untrue statement or omission; provided that (subject to Section&nbsp;6(d) below) any such settlement is effected with the written consent of the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;against any and all expense whatsoever, as incurred (including the fees and disbursements of
counsel chosen by the Representatives), reasonably incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission, to the extent
that any such expense is not paid under (i)&nbsp;or (ii) above; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided, however, that this indemnity agreement shall not apply to any loss, liability,
claim, damage or expense to the extent arising out of any untrue statement or omission or alleged untrue statement or omission made in the Registration Statement (or any amendment thereto), including any information deemed to be a part thereof
pursuant to Rule 430B, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with the Underwriter Information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Indemnification of Company, Directors and Officers</I>. Each Underwriter severally agrees to indemnify and hold
harmless the Company, its directors, each of its officers who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of the 1933 Act or Section&nbsp;20 of the 1934 Act, against any
and all loss, liability, claim, damage and expense described in the indemnity contained in subsection (a)&nbsp;of this Section, as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions, made in
the Registration Statement (or any amendment thereto), including any information deemed to be a part thereof pursuant to Rule 430B, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto) in reliance upon and in
conformity with the Underwriter Information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>Actions against Parties; Notification</I>. Each indemnified
party shall give notice as promptly as reasonably practicable to each indemnifying party of any action commenced against it in respect of which indemnity may be sought hereunder, but failure to so notify an indemnifying party shall not relieve such
indemnifying party from any liability hereunder to the extent it is not materially prejudiced as a result thereof and in any event shall not relieve it from any liability which it may have otherwise than on account of this indemnity agreement. In
the case of parties indemnified pursuant to Section&nbsp;6(a) above, counsel to the indemnified parties shall be selected by the Representatives, and, in the case of parties indemnified pursuant to Section&nbsp;6(b) above, counsel to the indemnified
parties shall be selected by the Company. An indemnifying party may participate at its own expense in the defense of any such action; provided, however, that counsel to the indemnifying party shall not (except with the consent of the indemnified
party) also be counsel to the indemnified party. In no event shall the indemnifying parties be liable for the reasonable fees and expenses of more than one counsel (in addition to any local counsel) separate from their own counsel for all
indemnified parties in connection with any one action or separate but similar or related actions in the same jurisdiction arising out of the same general allegations or circumstances. No indemnifying party shall, without the prior written consent of
the indemnified parties, settle or compromise or consent to the entry of any judgment with respect to any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever in respect
of which indemnification or contribution could be sought under this Section&nbsp;6 or Section&nbsp;7 hereof (whether or not the indemnified parties are actual or potential parties thereto), unless such settlement, compromise or consent
(i)&nbsp;includes an unconditional release of each indemnified party from all liability arising out of such litigation, investigation, proceeding or claim and (ii)&nbsp;does not include a statement as to or an admission of fault, culpability or a
failure to act by or on behalf of any indemnified party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<I>Settlement without Consent if Failure to
Reimburse</I>. If at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement of the
nature contemplated by Section&nbsp;6(a)(ii) effected without its written consent if (i)&nbsp;such settlement is entered into more than 45 days after receipt by such indemnifying party of the aforesaid request, (ii)&nbsp;such indemnifying party
shall have received notice of the terms of such settlement at least 30 days prior to such settlement being entered into and (iii)&nbsp;such indemnifying party shall not have reimbursed such indemnified party in accordance with such request prior to
the date of such settlement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Contribution</U>. If the indemnification provided for in
Section&nbsp;6 hereof is for any reason unavailable to or insufficient to hold harmless an indemnified party in respect of any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying party shall contribute to the
aggregate amount of such losses, liabilities, claims, damages and expenses incurred by such indemnified party, as incurred, (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and
the Underwriters, on the other hand, from the offering of the Securities pursuant to this Agreement or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;is not permitted by applicable law, in such proportion as is appropriate to reflect not
only the relative benefits referred to in clause (i)&nbsp;above but also the relative fault of the Company, on the one hand, and of the Underwriters, on the other hand, in connection with the statements or omissions which resulted in such losses,
liabilities, claims, damages or expenses, as well as any other relevant equitable considerations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The relative benefits received by the
Company, on the one hand, and the Underwriters, on the other hand, in connection with the offering of the Securities pursuant to this Agreement shall be deemed to be in the same respective proportions as the total net proceeds from the offering of
the Securities pursuant to this Agreement (before deducting expenses) received by the Company, on the one hand, and the total underwriting discount received by the Underwriters, on the other hand, in each case as set forth on the cover of the
Prospectus, bear to the aggregate initial public offering price of the Securities as set forth on the cover of the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
relative fault of the Company, on the one hand, and the Underwriters, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission
to state a material fact relates to information supplied by the Company or by the Underwriters and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this Section&nbsp;7 were determined
by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to above in this Section&nbsp;7. The aggregate
amount of losses, liabilities, claims, damages and expenses incurred by an indemnified party and referred to above in this Section&nbsp;7 shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in
investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue or alleged untrue statement or omission
or alleged omission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the provisions of this Section&nbsp;7, no Underwriter shall be required to contribute any amount in
excess of the underwriting discounts and commissions received by such Underwriter in connection with the Securities underwritten by it and distributed to the public. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the 1933 Act) shall be entitled to contribution
from any person who was not guilty of such fraudulent misrepresentation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Section&nbsp;7, each person, if any, who
controls an Underwriter within the meaning of Section&nbsp;15 of the 1933 Act or Section&nbsp;20 of the 1934 Act and each Underwriter&#146;s Affiliates and selling agents shall have the same rights to contribution as such Underwriter, and each
director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of the 1933 Act or Section&nbsp;20 of the 1934 Act shall have the
same rights to contribution as the Company. The Underwriters&#146; respective obligations to contribute pursuant to this Section&nbsp;7 are several in proportion to the number of Initial Securities set forth opposite their respective names in
<U>Schedule</U><U></U><U>&nbsp;A</U> hereto and not joint. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8.&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations, Warranties and Agreements to Survive</U>.
All representations, warranties and agreements contained in this Agreement or in certificates of officers of the Company or any of its Subsidiaries submitted pursuant hereto, shall remain operative and in full force and effect regardless of
(i)&nbsp;any investigation made by or on behalf of any Underwriter or its Affiliates or selling agents, any person controlling any Underwriter, its officers or directors or any person controlling the Company and (ii)&nbsp;delivery of and payment for
the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination of Agreement</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Termination</I>. The Representatives may terminate this Agreement, by notice to the Company, at any time at or
prior to the Closing Time (i)&nbsp;if there has been, in the judgment of the Representatives, since the time of execution of this Agreement or since the respective dates as of which information is given in the Registration Statement, the General
Disclosure Package or the Prospectus, any Material Adverse Effect, or (ii)&nbsp;if there has occurred any material adverse change in the financial markets in the United States or the international financial markets, any outbreak of hostilities or
escalation thereof or other calamity or crisis or any change or development involving a prospective change in U.S. or international political, financial or economic conditions, in each case the effect of which is such as to make it, in the judgment
of the Representatives, impracticable or inadvisable to proceed with the completion of the offering or to enforce contracts for the sale of the Securities, or (iii)&nbsp;if trading in any securities of the Company has been suspended or materially
limited by the Commission or the Nasdaq Capital Market, or (iv)&nbsp;if trading generally on the NYSE American or the New York Stock Exchange or in the Capital Global Market has been suspended or materially limited, or minimum or maximum prices for
trading have been fixed, or maximum ranges for prices have been required, by any of said exchanges or by order of the Commission, FINRA or any other governmental authority, or (v)&nbsp;a material disruption has occurred in commercial banking or
securities settlement or clearance services in the United States or with respect to Clearstream or Euroclear systems in Europe, or (vi)&nbsp;if a banking moratorium has been declared by either Federal or New York authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Liabilities</I>. If this Agreement is terminated pursuant to this Section, such termination shall be without
liability of any party to any other party except as provided in Section&nbsp;4 hereof, and provided further that Sections 1, 4, 6, 7, 8, 14, 15 and 16 shall survive such termination and remain in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Default by One or More of the Underwriters</U>. If one or more of the Underwriters shall fail at the
Closing Time or a Date of Delivery to purchase the Securities which it or they are obligated to purchase under this Agreement (the &#147;<U>Defaulted Securities</U>&#148;), the Representatives shall have the right, within 24&nbsp;hours thereafter,
to make arrangements for one or more of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, or any other underwriters, to purchase all, but not less than all, of the Defaulted Securities in such amounts as may be agreed upon and
upon the terms herein set forth; if, however, the Representatives shall not have completed such arrangements within such <FONT STYLE="white-space:nowrap">24-hour</FONT> period, then: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;if the number of Defaulted Securities does not exceed 10% of the number of Securities to be
purchased on such date, each of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters shall be obligated, severally and not jointly, to purchase the full amount thereof in the proportions that their respective underwriting
obligations hereunder bear to the underwriting obligations of all <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;if the number of Defaulted Securities exceeds 10% of
the number of Securities to be purchased on such date, this Agreement or, with respect to any Date of Delivery which occurs after the Closing Time, the obligation of the Underwriters to purchase, and the Company to sell, the Option Securities to be
purchased and sold on such Date of Delivery shall terminate without liability on the part of any <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No action taken pursuant to this Section shall relieve any defaulting Underwriter from liability in respect of its default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of any such default which does not result in a termination of this Agreement or, in the case of a Date of Delivery which is after
the Closing Time, which does not result in a termination of the obligation of the Underwriters to purchase and the Company to sell the relevant Option Securities, as the case may be, either the (i)&nbsp;Representatives or (ii)&nbsp;the Company shall
have the right to postpone Closing Time or the relevant Date of Delivery, as the case may be, for a period not exceeding seven days in order to effect any required changes in the Registration Statement, the General Disclosure Package or the
Prospectus or in any other documents or arrangements. As used herein, the term &#147;Underwriter&#148; includes any person substituted for an Underwriter under this Section&nbsp;10. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 11.&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>. All notices and other communications hereunder shall be in writing and shall be deemed to
have been duly given if mailed or transmitted by any standard form of telecommunication. Notices to the Underwriters shall be directed to Leerink at One Federal Street, Floor 37, Boston, MA 02110, attention of John I. Fitzgerald, Esq. (facsimile: <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-918-4664)</FONT></FONT> and to Piper Jaffray at Piper Jaffray&nbsp;&amp; Co., 800 Nicollet Mall, Minneapolis, MN 55402, Attention: Equity Capital Markets (fax: (612) <FONT
STYLE="white-space:nowrap">303-1070</FONT> and email: LegalCapMarkets@pjc.com) and Attention: General Counsel (fax: (612) <FONT STYLE="white-space:nowrap">303-1068)</FONT> with a copy to Goodwin Procter LLP, 620 Eighth Avenue, New York, NY 10018,
attention of Michael Maline (facsimile: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">212-355-3333)</FONT></FONT> and to Synlogic, Inc., 200 Sidney Street, Suite 320, Cambridge, MA 02139, attention: General Counsel with a copy to
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111, fax <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">no.&nbsp;617-542-2241,&nbsp;Attention:</FONT></FONT> Matthew J. Gardella. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 12.&nbsp;&nbsp;&nbsp;&nbsp;<U>No Advisory or Fiduciary Relationship</U>. The Company acknowledges and agrees that (a)&nbsp;the
purchase and sale of the Securities pursuant to this Agreement, including the determination of the initial public offering price of the Securities and any related discounts and commissions, is an
<FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> commercial transaction between the Company, on the one hand, and the several Underwriters, on the other hand, (b)&nbsp;in connection with the offering of the Securities and the process
leading thereto, each Underwriter is and has been acting solely as a principal and is not the agent or fiduciary of the Company, any of its Subsidiaries or their respective stockholders, creditors, employees or any other party, (c)&nbsp;no
Underwriter has assumed or will assume an advisory or fiduciary responsibility in favor of the Company with respect to the offering of the Securities or the process leading thereto (irrespective of whether such Underwriter has advised or is
currently advising the Company or any of its Subsidiaries on other matters) and no Underwriter has any obligation to the Company with respect to the offering of the Securities except the obligations expressly set forth in this Agreement,
(d)&nbsp;the Underwriters and their respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company and (e)&nbsp;the Underwriters have not provided any legal, accounting, regulatory
or tax advice with respect to the offering of the Securities and the Company has consulted its own respective legal, accounting, regulatory and tax advisors to the extent it deemed appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 13.&nbsp;&nbsp;&nbsp;&nbsp;<U>Parties</U>. This Agreement shall each inure to the benefit of and be binding upon the Underwriters and
the Company and their respective successors. Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any person, firm or corporation, other than the Underwriters and the Company and their respective successors and
the controlling persons and officers and directors referred to in Sections&nbsp;6 and 7 and their heirs and legal representatives, any legal or equitable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
right, remedy or claim under or in respect of this Agreement or any provision herein contained. This Agreement and all conditions and provisions hereof are intended to be for the sole and
exclusive benefit of the Underwriters and the Company and their respective successors, and said controlling persons and officers and directors and their heirs and legal representatives, and for the benefit of no other person, firm or corporation. No
purchaser of Securities from any Underwriter shall be deemed to be a successor by reason merely of such purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION
14.&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver of Trial by Jury</U>. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders and affiliates) and each of the Underwriters hereby irrevocably waives, to the
fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 15.&nbsp;&nbsp;&nbsp;&nbsp;<U>GOVERNING LAW</U>. THIS AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS
AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF, THE STATE OF NEW YORK WITHOUT REGARD TO ITS CHOICE OF LAW PROVISIONS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 16.&nbsp;&nbsp;&nbsp;&nbsp;<U>Consent to Jurisdiction; Waiver of Immunity</U>. Any legal suit, action or proceeding arising out of or
based upon this Agreement or the transactions contemplated hereby shall&nbsp;be instituted in (i)&nbsp;the federal courts of the United States of America located in the City and County of New York, Borough of Manhattan or&nbsp;(ii) the courts of the
State of New York located in the City and County of New York, Borough of Manhattan (collectively, the &#147;<U>Specified Courts</U>&#148;), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard
to the enforcement of a judgment of any such court, as to which such jurisdiction is <FONT STYLE="white-space:nowrap">non-exclusive)</FONT> of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by
mail to such party&#146;s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any
suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an
inconvenient forum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 17.&nbsp;&nbsp;&nbsp;&nbsp;<U>TIME</U>. TIME SHALL BE OF THE ESSENCE OF THIS AGREEMENT. EXCEPT AS OTHERWISE
SET FORTH HEREIN, SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 18.&nbsp;&nbsp;&nbsp;&nbsp;<U>Partial Unenforceability</U>.
The invalidity or unenforceability of any Section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other Section, paragraph or provision hereof. If any Section, paragraph or provision of this Agreement
is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 19.&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>. This Agreement may be executed in any number of counterparts (which may include
counterparts delivered by any standard form of telecommunication), each of which shall be deemed to be an original, but all such counterparts shall together constitute one and the same agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 20.&nbsp;&nbsp;&nbsp;&nbsp;<U>Effect of Headings</U>. The Section headings herein are for convenience only and shall not affect the
construction hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 21.&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire Agreement</U>. This Agreement supersedes all prior agreements and
understandings (whether written or oral) between the Company and the Underwriters, or any of them, with respect to the subject matter hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[SIGNATURE PAGES FOLLOW] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding of our agreement, please sign and
return to the Company a counterpart hereof, whereupon this instrument, along with all counterparts, will become a binding agreement among the Underwriters and the Company in accordance with its terms. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SYNLOGIC, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jose Carlos Guti&eacute;rrez-Ramos</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Jose Carlos Guti&eacute;rrez-Ramos</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CONFIRMED AND ACCEPTED</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">As of the date first above written:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">LEERINK PARTNERS LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John. I. Fitzgerald</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: John I. Fitzgerald, Esq.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">PIPER JAFFRAY&nbsp;&amp; CO.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David W. Stadinski</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: David W. Stadinski</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Managing Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For themselves and as Representatives of the other Underwriters named in <U>Schedule</U><U></U><U>&nbsp;A</U> hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> U<SMALL>NDERWRITING</SMALL> A<SMALL>GREEMENT</SMALL>] </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SCHEDULE A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The initial public offering price per share for the Securities shall be $9.75. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purchase price per share for the Securities to be paid by the several Underwriters shall be $9.165, being an amount equal to the initial public offering
price set forth above less $0.585 per share, subject to adjustment in accordance with Section&nbsp;2(b) for dividends or distributions declared by the Company and payable on the Initial Securities but not payable on the Option Securities. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:68.80pt; font-size:8pt; font-family:Times New Roman">Name of Underwriter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number&nbsp;of<br>Initial&nbsp;Securities</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,565,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Piper Jaffray&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,052,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">H.C. Wainright&nbsp;&amp; Co., LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">513,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,130,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SCHEDULE <FONT STYLE="white-space:nowrap">B-1</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Pricing Terms </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;The Company is selling 5,130,000 shares of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;The Company has granted an option to the Underwriters, severally and not jointly, to purchase up to an additional 769,500 shares of
Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;The initial public offering price per share for the Securities shall be $9.75. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SCHEDULE <FONT STYLE="white-space:nowrap">B-2</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Free Writing Prospectuses </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SCHEDULE <FONT STYLE="white-space:nowrap">B-3</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>List of Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Presentation &#150; January 2018 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SCHEDULE C </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>List of Subsidiaries </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Synlogic Operating
Company, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Synlogic Securities Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Synlogic
IBDCo, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SCHEDULE D </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Parties </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jose Carlos Gutierrez-Ramos, Ph.D. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Todd Shegog </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Andrew Gengos </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aoife Brennan, MB, BCh, BAO, MMSc </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paul Miller, Ph.D. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Peter Barrett, Ph.D. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chau Khuong </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nick Leschly </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Edward Mathers </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael Powell, Ph.D. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Richard P. Shea </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Atlas Venture Fund IX, L.P. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Enterprise Associates 14, L.P. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Orbimed Private Investments
VI, L.P. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sofinnova Venture Partners VIII, L.P. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Piper Jaffray&nbsp;&amp; Co. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">as Representatives of the several Underwriters </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Leerink
Partners LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">299 Park Avenue, 21st floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10171
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Piper Jaffray&nbsp;&amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">800 Nicollet Mall </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Minneapolis, Minnesota 55402 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Re:&nbsp;&nbsp;&nbsp;&nbsp;<U>Proposed Public Offering by Synlogic, Inc.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned, a
stockholder, officer and/or director of Synlogic, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), understands that Leerink Partners LLC (&#147;<U>Leerink</U>&#148;) and Piper Jaffray&nbsp;&amp; Co. (&#147;Piper Jaffray&#148;) propose
to enter into an Underwriting Agreement (the &#147;<U>Underwriting Agreement</U>&#148;) with the Company providing for the public offering (the &#147;<U>Public Offering</U>&#148;) of shares (the &#147;<U>Securities</U>&#148;) of the Company&#146;s
common stock, par value $0.001 per share (the &#147;<U>Common Stock</U>&#148;). In recognition of the benefit that such an offering will confer upon the undersigned as a stockholder, an officer and/or a director of the Company, and for other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees with each underwriter to be named in the Underwriting Agreement (collectively, the &#147;<U>Underwriters</U>&#148;) that, during the
period beginning on the date hereof and ending on the date that is 90 days from the date of the Underwriting Agreement (the &#147;<U><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</U>&#148;), the undersigned will not, without the prior
written consent of Leerink and Piper Jaffray, on behalf of the Underwriters, directly or indirectly, (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option,
right or warrant for the sale of, or otherwise dispose of or transfer any shares of Common Stock or any securities convertible into or exchangeable or exercisable for Common Stock, whether now owned or hereafter acquired by the undersigned or with
respect to which the undersigned has or hereafter acquires the power of disposition (collectively, the &#147;<U><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities</U>&#148;), or exercise any right with respect to the registration of any of
the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, or file or cause to be filed any registration statement in connection therewith, under the Securities Act of 1933, as amended, or (ii)&nbsp;enter into any swap or any other agreement or
any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, whether any such swap or transaction is to be settled by delivery
of Common Stock or other securities, in cash or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, and subject to the conditions below, the
undersigned may transfer <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities without the prior written consent of Leerink and Piper Jaffray, provided, in each case, that (1)&nbsp;Leerink and Piper Jaffray receives a signed <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreement for the balance of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period from each donee, trustee, distributee, or transferee, as the case may be, (2)&nbsp;any such transfer shall not involve
a disposition for value, (3)&nbsp;such transfers are not required to be reported with the Securities and Exchange Commission on Form 4 in accordance with Section&nbsp;16 of the Securities Exchange Act of 1934,
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as amended (the &#147;<U>Exchange Act</U>&#148;), and (4)&nbsp;the undersigned does not otherwise voluntarily effect any public filing or report regarding such transfers (other than a filing on a
Form 5 made after the expiration of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">as a <I>bona fide</I> gift or gifts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned (for purposes of this <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, &#147;immediate family&#148;
shall mean any relationship by blood, marriage or adoption, not more remote than first cousin); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">as a distribution or other transfer by a partnership to its partners or former partners or by a limited liability company to its members or retired members or by a corporation to its stockholders or former stockholders
or to any wholly-owned subsidiary of such corporation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top">to the undersigned&#146;s affiliates or to any investment fund or other entity controlled or managed by the undersigned; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top">pursuant to a qualified domestic relations order or in connection with a divorce settlement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top">by will or intestate succession upon the death of the undersigned; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top">to the Company in satisfaction of any tax withholding obligation. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, no provision
in this letter shall be deemed to restrict or prohibit (1)&nbsp;the transfer of the undersigned&#146;s <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities to the Company in connection with the termination of the undersigned&#146;s services to
the Company, provided that any filing under Section&nbsp;16 of the Exchange Act made in connection with such transfer shall clearly indicate in the footnotes thereto that the filing relates to the circumstances described in this clause (1); (2) the
exercise or exchange by the undersigned of any option or warrant to acquire any shares of Common Stock or options to purchase shares of Common Stock, in each case for cash or on a &#147;cashless&#148; or &#147;net exercise&#148; basis, pursuant to
any stock option, stock bonus or other stock plan or arrangement; provided, however, that the underlying shares of Common Stock shall continue to be subject to the restrictions on transfer set forth in this letter and that any filing under
Section&nbsp;16 of the Exchange Act made in connection with such exercise or exchange shall clearly indicate in the footnotes thereto that (a)&nbsp;the filing relates to the circumstances described in this clause (2)&nbsp;and (b) no shares were sold
by the reporting person; (3)&nbsp;the transfer of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities upon the completion of a bona fide third-party tender offer, merger, consolidation or other similar transaction made to all holders of the
Company&#146;s securities involving a change of control of the Company; provided, however, that in the event that such tender offer, merger, consolidation or other such transaction is not completed, such securities held by the undersigned shall
remain subject to the restrictions on transfer set forth in this letter; and (4)&nbsp;sales or transfers of Securities acquired on the open market after the date of the Underwriting Agreement, provided that no such transaction is required to be, or
is, publicly announced (whether on Form 4, Form 5 or otherwise) during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything herein to the contrary, nothing herein shall prevent the undersigned from establishing a <FONT
STYLE="white-space:nowrap">10b5-1</FONT> trading plan that complies with Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act (&#147;<U><FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan</U>&#148;) or from amending an
existing <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan so long as there are no sales of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities under any such <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period; and provided that, the establishment of a <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan or the amendment of a <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan shall only be
permitted if (i)&nbsp;the establishment or amendment of such plan is not required to be reported in any public report or filing with the Securities Exchange Commission, or otherwise and (ii)&nbsp;the undersigned does not otherwise voluntarily effect
any public filing or report regarding the establishment or amendment of such plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned also agrees and consents to the entry of stop transfer instructions with the
Company&#146;s transfer agent and registrar against the transfer of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities except in compliance with the foregoing restrictions. This <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement
shall automatically terminate, and the undersigned shall be released from the undersigned&#146;s obligations hereunder, upon the earliest to occur, if any, of (i)&nbsp;prior to the execution of the Underwriting Agreement, the Company advises Leerink
and Piper Jaffray in writing that it has determined not to proceed with the Public Offering; (ii)&nbsp;the Underwriting Agreement is executed but is terminated prior to the closing of the Public Offering (other than the provisions thereof which
survive termination), or (iii)&nbsp;February&nbsp;24, 2018, in the event that the Underwriting Agreement has not been executed by such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This agreement shall be governed by, and construed in accordance with, the laws of the State of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[SIGNATURE PAGE FOLLOWS] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name of Security Holder (<I>Print exact name</I>)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-bottom:1pt; margin-top:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">If not signing in an individual capacity:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name of Authorized Signatory <I>(Print</I>)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title of Authorized Signatory <I>(Print</I>)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><I>(indicate capacity of person signing if signing as custodian, trustee, or on behalf of an entity)</I></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d514974dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="27%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g514974000.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">One Financial Center</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Boston, MA 02111</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-542-6000</FONT></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">617-542-2241</FONT></FONT> fax</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">www.mintz.com</P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">January&nbsp;23, 2018 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Synlogic, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 Sidney St., Suite 320 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02139 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is
furnished to you in connection with a Prospectus Supplement, dated January&nbsp;23, 2018, to a Prospectus dated October&nbsp;13, 2017 (the &#147;<B>Prospectus and Prospectus Supplement</B>&#148;), filed pursuant to a Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-3,</FONT> Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-220948</FONT> (the &#147;<B>Registration Statement</B>&#148;), filed by Synlogic, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), with
the Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) under the Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;), with respect to an aggregate of 5,899,500 shares (the &#147;<B>Shares</B>&#148;) of its
common stock, $0.001 par value per share (the &#147;<B>Common Stock</B>&#148;), which includes 769,500 shares of Common Stock that may be sold pursuant to the exercise of an option to purchase additional shares. The Shares are to be sold pursuant to
an Underwriting Agreement (the &#147;<B>Underwriting Agreement</B>&#148;) dated January&nbsp;23, 2018 by and among the Company and Leerink Partners LLC and Piper Jaffray&nbsp;&amp; Co., as representatives of the underwriters listed in Schedule A
thereto, which will be filed as an exhibit to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and incorporated by reference into the Registration Statement. All capitalized terms used herein and not otherwise defined shall have
the respective meanings given to them in the Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this opinion, we have examined originals or
copies, certified or otherwise identified to our satisfaction, of: (i)&nbsp;the Amended and Restated Certificate of Incorporation of the Company, as amended through the date hereof; (ii)&nbsp;the Amended and Restated Bylaws of the Company, as
amended through the date hereof; (iii)&nbsp;certain resolutions of the Board of Directors of the Company (the &#147;<B>Board</B>&#148;) relating to the issuance, sale and registration of the Shares; (iv)&nbsp;the Registration Statement; (v)&nbsp;the
Underwriting Agreement; (vi)&nbsp;the Registration Statement, together with the exhibits thereto filed with the Commission; and (vii)&nbsp;the Prospectus and Prospectus Supplement. In addition, we have examined originals or copies, certified or
otherwise identified to our satisfaction, of certain other corporate records, documents, instruments and certificates of public officials and of the Company, and we have made such inquiries of officers of the Company and public officials and
considered such questions of law as we have deemed necessary for purposes of rendering the opinions set forth herein. Our opinions are limited to the matters stated herein and no opinion is implied or may be inferred beyond the matters expressly
stated. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not sought to independently verify such matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our examination, we have assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity of all
documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified or photostatic copies and the authenticity of the originals of such copies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Mintz, Levin, Cohn,
Ferris, Glovsky and Popeo, P.C. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B<SMALL>OSTON</SMALL> | W<SMALL>ASHINGTON</SMALL> | N<SMALL>EW</SMALL> Y<SMALL>ORK</SMALL> |
S<SMALL>TAMFORD</SMALL> | L<SMALL>OS</SMALL> A<SMALL>NGELES</SMALL> | S<SMALL>AN</SMALL> F<SMALL>RANCISCO</SMALL> | S<SMALL>AN</SMALL> D<SMALL>IEGO</SMALL> | L<SMALL>ONDON</SMALL> </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">M<SMALL>INTZ</SMALL>, L<SMALL>EVIN</SMALL>, C<SMALL>OHN</SMALL>, F<SMALL>ERRIS</SMALL>,
G<SMALL>LOVSKY</SMALL> <SMALL>AND</SMALL> P<SMALL>OPEO</SMALL>, P.C. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">January 23, 2018 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 2 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our opinion is limited to the General Corporation Law of the State of Delaware and we express
no opinion with respect to the laws of any other jurisdiction. No opinion is expressed herein with respect to the qualification of the Shares under the securities or blue sky laws of any state or any foreign jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters.
This opinion is based upon currently existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources of law or subsequent legal or factual developments which might
affect any matters or opinions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon the foregoing, we are of the opinion that the Shares have been authorized for
issuance and, when the Shares are issued and paid for in accordance with the Underwriting Agreement, the Shares will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We understand that you wish to file this opinion with the Commission as an exhibit to a Current Report on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> for incorporation by reference into the Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> promulgated under the
Securities Act and to reference the firm&#146;s name under the caption &#147;Legal Matters&#148; in the Prospectus Supplement, and we hereby consent thereto. In giving this consent, we do not admit that we are within the category of persons whose
consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours,
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>/s/ Mintz, Levin, Cohn, Ferris, Glovsky&nbsp;&amp; Popeo, P.C. </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mintz, Levin, Cohn, Ferris, Glovsky&nbsp;&amp; Popeo, P.C. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Mintz, Levin, Cohn,
Ferris, Glovsky and Popeo, P.C. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B<SMALL>OSTON</SMALL> | W<SMALL>ASHINGTON</SMALL> | N<SMALL>EW</SMALL> Y<SMALL>ORK</SMALL> |
S<SMALL>TAMFORD</SMALL> | L<SMALL>OS</SMALL> A<SMALL>NGELES</SMALL> | S<SMALL>AN</SMALL> F<SMALL>RANCISCO</SMALL> | S<SMALL>AN</SMALL> D<SMALL>IEGO</SMALL> | L<SMALL>ONDON</SMALL> </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>d514974dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g514974g96v72.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Exhibit 99.1</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Synlogic Announces Proposed Public Offering of Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">January&nbsp;23, 2018 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CAMBRIDGE, Mass.&#151;(BUSINESS
WIRE)&#151;Jan. 23, 2018&#151; <U>Synlogic (Nasdaq: SYBX)</U> a clinical-stage company applying synthetic biology to probiotics to develop novel living medicines, today announced that it has commenced an underwritten public offering of its common
stock. All shares of common stock to be sold in the offering will be offered by Synlogic. Synlogic intends to grant the underwriters a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to an aggregate of an additional 15% of the
shares of its common stock offered in the public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leerink Partners and Piper Jaffray&nbsp;&amp; Co. are acting as joint book-running managers for the offering. H.C. Wainwright&nbsp;&amp; Co. is acting as
lead manager for the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Synlogic intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, as
follows: to fund its two planned Phase 1b/2a clinical trials of SYNB1020 (one study involving HE patients and the other study involving UCD patients) through completion; to fund activities in process development, formulation and toxicology as needed
for subsequent initiation of a Phase 2b clinical trial in patients with liver cirrhosis with elevated blood ammonia; to fund its planned Phase 1/2a clinical trial of SYNB1618 through completion and to support acceleration of a Phase 2b clinical
trial of SYNB1618 for PKU patients and continued process development and formulation activities; to fund further preclinical development in its immuno-oncology programs and drug discovery activities in its other programs; and for working capital and
general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities described above are being offered by Synlogic pursuant to its shelf registration statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-220948)</FONT> filed with the Securities Exchange Commission (the &#147;SEC&#148;) on October&nbsp;13, 2017 and declared effective by the SEC on
October&nbsp;25, 2017. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC&#146;s website at <U>https://www.sec.gov/</U>. When available, copies of the
preliminary prospectus supplement and the accompanying prospectus relating to the offering may be obtained from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) <FONT
STYLE="white-space:nowrap">808-7525</FONT> ext. 6132 or by email at <U>syndicate@leerink.com</U>; or from Piper Jaffray&nbsp;&amp; Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attention: Prospectus Department, by telephone at (800) <FONT
STYLE="white-space:nowrap">747-3924,</FONT> or by email at <U>prospectus@pjc.com</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any sale of these securities, in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the
securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of the prospectus supplement and accompanying prospectus forming a part of the effective registration statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Synlogic </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Synlogic is pioneering the development of
a novel class of living medicines, Synthetic Biotic&#153; medicines, based on its proprietary drug development platform. Synlogic&#146;s initial pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as urea
cycle disorders (UCD) and phenylketonuria (PKU). In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of more common diseases, including liver disease, inflammatory and
immune disorders, and cancer. Synlogic is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease (IBD). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This release contains
&#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Synlogic&#146;s expectations with respect to its proposed offering, its intention to grant the
underwriters an option to purchase additional shares and its intended use of proceeds from the offering. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and
assumptions, including the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed public offering, as well as risks and uncertainties inherent in Synlogic&#146;s
business, including those described in the company&#146;s periodic filings with the SEC. The events and circumstances reflected in the company&#146;s forward-looking statements may not be achieved or occur and actual results could differ materially
from those projected in the forward-looking statements. Additional information on risks facing Synlogic can be found under the heading &#147;Risk Factors&#148; in Synlogic&#146;s periodic reports, including its quarterly report on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended September&nbsp;30, 2017, and in the preliminary prospectus supplement related to the proposed offering to be filed with the SEC on or about the date hereof, each available on the
SEC&#146;s web site at www.sec.gov. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed
circumstances or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">View source version on businesswire.com: <U>http://www.businesswire.com/news/home/20180123006452/en/</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Source: Synlogic </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Synlogic </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MEDIA
CONTACT: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Courtney Heath, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-872-2462</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>courtney@scientpr.com</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR CONTACT: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Elizabeth Wolffe, Ph.D., <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-207-5509</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>liz@synlogictx.com</U> </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>5
<FILENAME>d514974dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g514974g0124092636874.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"><B>MEDIA CONTACT:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>INVESTOR CONTACT:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Courtney Heath</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Phone: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-872-2462</FONT></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Email: courtney@scientpr.com</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elizabeth Wolffe, Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Phone: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-207-5509</FONT></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Email: liz@synlogictx.com</P></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Synlogic Announces Pricing of Public Offering of Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cambridge, Mass. (Business Wire) January</B><B></B><B>&nbsp;24, 2018 </B>&#150; <U>Synlogic (Nasdaq: SYBX)</U> a clinical-stage company applying synthetic
biology to probiotics to develop novel living medicines, today announced the pricing of its underwritten public offering of 5,130,000 shares of its common stock at a public offering price of $9.75 per share. The gross proceeds to Synlogic from the
offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Synlogic, are expected to be $50,017,500. All shares of common stock to be sold in the offering are being sold by Synlogic. In addition,
Synlogic has granted to the underwriters a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to 769,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is
expected to close on or about January&nbsp;26, 2018, subject to the satisfaction of customary closing conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leerink Partners and Piper Jaffray
&amp; Co. are acting as joint book-running managers for the offering. H.C. Wainwright&nbsp;&amp; Co. is acting as lead manager for the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Synlogic
intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, as follows: to fund its two planned Phase 1b/2a clinical trials of SYNB1020 (one study involving HE patients and the other study involving UCD
patients) through completion; to fund activities in process development, formulation and toxicology as needed for subsequent initiation of a Phase 2b clinical trial in patients with liver cirrhosis with elevated blood ammonia; to fund its planned
Phase 1/2a clinical trial of SYNB1618 through completion and to support acceleration of a Phase 2b clinical trial of SYNB1618 for PKU patients and continued process development and formulation activities; to fund further preclinical development in
its immuno-oncology programs and drug discovery activities in its other programs; and for working capital and general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities
described above are being offered by Synlogic pursuant to its shelf registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-220948)</FONT> filed with the Securities Exchange
Commission (the &#147;SEC&#148;) on October&nbsp;13, 2017 and declared effective by the SEC on October&nbsp;25, 2017. A preliminary prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC and a final
prospectus supplement and the accompanying prospectus relating to this offering will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from
Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) <FONT STYLE="white-space:nowrap">808-7525</FONT> ext. 6132 or by email at syndicate@leerink.com; or from Piper
Jaffray&nbsp;&amp; Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page<B> 1</B> of <B>2</B>
</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g514974g0124092636874.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Prospectus Department, by telephone at
(800) <FONT STYLE="white-space:nowrap">747-3924,</FONT> or by email at prospectus@pjc.com. The preliminary prospectus supplement and accompanying prospectus is also available, and the final prospectus supplement and accompanying prospectus will be
available, on the SEC&#146;s website at http://www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release shall not constitute an offer to sell or the solicitation of an offer to
buy these securities, nor shall there be any sale of these securities, in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state
or other jurisdiction. Any offer, if at all, will be made only by means of the prospectus supplement and accompanying prospectus forming a part of the effective registration statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Synlogic </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Synlogic is pioneering the development of
a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform. Synlogic&#146;s initial pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as urea cycle
disorders (UCD) and phenylketonuria (PKU). In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of more common diseases, including liver disease, inflammatory and immune
disorders, and cancer. Synlogic is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease (IBD). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This release contains
&#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Synlogic&#146;s ability to complete the offering and its expected and intended use of proceeds from the
offering. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties associated with market conditions and the
satisfaction of customary closing conditions related to the proposed public offering, as well as risks and uncertainties inherent in Synlogic&#146;s business, including those described in the company&#146;s periodic filings with the SEC. The events
and circumstances reflected in the company&#146;s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing
Synlogic can be found under the heading &#147;Risk Factors&#148; in Synlogic&#146;s periodic reports, including its quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended September&nbsp;30, 2017, and in the
preliminary prospectus supplement related to the proposed offering to be filed with the SEC on or about the date hereof, each available on the SEC&#146;s web site at www.sec.gov. Except as required by applicable law, the company does not plan to
publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page <B>1</B> of <B>2</B>
</P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g514974000.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g514974000.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^(,6$E#
M0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8
M,0  86-S<$U31E0     245#('-21T(               $  /;6  $
MTRU(4" @
M           18W!R=    5     S9&5S8P   80   !L=W1P=    ?     4
M8FMP=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D
M   49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P
M ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E12
M0P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y
M<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M        $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V
M,3DV-BTR+C$
M                 %A96B        #S40 !     1;,6%E:(
M          !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4
M !C:6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO
M+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M
M9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N,2!$969A=6QT
M(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)
M14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD
M:71I;VX@:6X@245#-C$Y-C8M,BXQ
M  !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@
M  !,"58 4    %<?YVUE87,          0                        */
M     G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ",
M*  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5
M )H GP"D *D K@"R +< O #! ,8 RP#0 -4 VP#@ .4 ZP#P /8 ^P$! 0<!
M#0$3 1D!'P$E 2L!,@$X 3X!10%, 5(!60%@ 6<!;@%U 7P!@P&+ 9(!F@&A
M :D!L0&Y <$!R0'1 =D!X0'I ?(!^@(# @P"% (= B8"+P(X D$"2P)4 ET"
M9P)Q GH"A *. I@"H@*L K8"P0++ M4"X +K O4#  ,+ Q8#(0,M S@#0P-/
M UH#9@-R WX#B@.6 Z(#K@.Z \<#TP/@ ^P#^00&!!,$( 0M!#L$2 15!&,$
M<01^!(P$F@2H!+8$Q 33!.$$\ 3^!0T%' 4K!3H%2058!6<%=P6&!98%I@6U
M!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L &T0;C!O4'!P<9!RL'
M/0=/!V$'= >&!YD'K >_!]('Y0?X" L('P@R"$8(6@AN"(((E@BJ"+X(T@CG
M"/L)$ DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5 IJ"H$*F JN"L4*
MW KS"PL+(@LY"U$+:0N "Y@+L O("^$+^0P2#"H,0PQ<#'4,C@RG#, ,V0SS
M#0T-)@U #5H-= V.#:D-PPW>#?@.$PXN#DD.9 Y_#IL.M@[2#NX/"0\E#T$/
M7@]Z#Y8/LP_/#^P0"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H
M$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4
MSA3P%1(5-!56%7@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2
M%_<8&QA &&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;
M.QMC&XH;LAO:' (<*AQ2''L<HQS,'/4='AU''7 =F1W#'>P>%AY 'FH>E!Z^
M'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/ A'"%((74AH2'.(?LB)R)5(H(B
MKR+=(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W
M)N@G&"=))WHGJR?<* TH/RAQ**(HU"D&*3@I:RF=*= J BHU*F@JFRK/*P(K
M-BMI*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'
M+_XP-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XT
MV#43-4TUAS7"-?TV-S9R-JXVZ3<D-V WG#?7.!0X4#B,.,@Y!3E".7\YO#GY
M.C8Z=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/> ^(#Y@/J ^X#\A/V$_
MHC_B0"- 9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/ 1 -$1T2*1,Y%$D55
M19I%WD8B1F=&JT;P1S5'>T? 2 5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+
MFDOB3"I,<DRZ30)-2DV33=Q.)4YN3K=/ $])3Y-/W5 G4'%0NU$&45!1FU'F
M4C%2?%+'4Q-37U.J4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8
MRUD:66E9N%H'6E9:IEKU6T5;E5OE7#5<AES672==>%W)7AI>;%Z]7P]?85^S
M8 5@5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD0&249.EE/6629>=F/6:29NAG
M/6>39^EH/VB6:.QI0VF::?%J2&J?:O=K3VNG:_]L5VRO;0AM8&VY;A)N:V[$
M;QYO>&_1<"MPAG#@<3IQE7'P<DMRIG,!<UUSN'04='!TS'4H=85UX78^=IMV
M^'=6=[-X$7AN>,QY*GF)>>=Z1GJE>P1[8WO"?"%\@7SA?4%]H7X!?F)^PG\C
M?X1_Y8!'@*B!"H%K@<V",(*2@O2#5X.ZA!V$@(3CA4>%JX8.AG*&UX<[AY^(
M!(AIB,Z),XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^>D :0;I#6
MD3^1J)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R:
M:)K5FT*;KYP<G(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/F
MI%:DQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN
M+:ZAKQ:OB[  L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9
MN-&Y2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7 <,#LP6?!X\)?PMO#
M6,/4Q%'$SL5+Q<C&1L;#QT''O\@]R+S).LFYRCC*M\LVR[;,-<RUS37-M<XV
MSK;/-\^XT#G0NM$\T;[2/]+!TT33QM1)U,O53M71UE76V-=<U^#89-CHV6S9
M\=IVVOO;@-P%W(K=$-V6WAS>HM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$
MY@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.] [\SP6/#E\7+Q
M__*,\QGSI_0T],+U4/7>]FWV^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+
M_MS_;?___^X )D%D;V)E &3      0, %00#!@H-   1/P  '@T  "(=   E
MY/_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$" @(! @(# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M_\( $0@ + #D P$1  (1 0,1 ?_$ -@   (" P #               (!PD%
M!@H! P0! 0                     0  $# @4"!04!          8$!0<"
M P$4%1<( !81$A,W&! P<"@X0!$   4"! ,%!@($"0T      0(#! 41$@ 3
M% 8A%0<Q02(C%E%A,D(D%Q!Q,S1TM#"!4F(EM39V"$"AL7*R0U-C1(1U1C<2
M 0                   ' 3 0 " 0,# 0@# 0        $ $2'P,4$046&A
M,'!Q@9&QP>$@0-'Q_]H # ,!  (1 Q$   &_L\@                 &*.:
M@Z.3<Q(!&"\8     -/.=$Z&210       JN(G+IRG@V<F<QX_8G9ZC3CUDT
MD4C\G/F=!QC!"#<#Z"="'CXS,DUFG$\'@00KT+-0%4-@&6%'' &W*JRTT14G
M$8@Y\3H./!3J/P)B,Z3$+N(N6C&$&G,:5'#VE4!:^5C$MC-$\E3Y=X5*EA@C
M0YI-IS4'00*B0F/60:;.3>+:;H*0.D-61N+D-Z:@1Z1^9 ]PS!JIDR B32&#
M8R9Q;#YS/&--E&0,:1&+V2T-*:$22?_:  @! 0 !!0+_ &K4EI>DY!8/<0'X
M\]H21CZY"'> +&7&$0N'(I]E^9$9$UF[$],7($9&&X3;ON2 )(CV9.)9JM3V
M?'HJ\TFO_#7VD))@)1L^.)O<XT<DZBTJ3$,EEK&<,LA2&_7QB9"TN?'*8#1I
M46">4KML*F5Y,SK#J4?Z_P"EE:JTD'9C,"<DN20>IG^))962ET=$JL0&;$BE
M5(0+2HZF0A%,OC<M-Q.\.+"UQ\9WSUA^C%79O<B^0C6XQ++DC2-2CCI6'(P*
M#.%RRF]&,H?TE)@^SE)*'/SQ )68X48RK;M6[-,#>[-:9-57-TB.0\BB^/6R
M-!+J4?Z_^D=$*=BG0),,#=SMX;7<D)&I[M>Y IPP N.7L>DC]\'P@%/AV5 Z
M$:;=$3=*E:9%9CDX&W3D;+ /8DD XGC)$_7I9>FAJCOA6^M%@7E%>BPY*'Y
MF;Y.-PL>D(; ZSX=EVJNFC"!%B2N63PW9(]&(+'U#LK)I#'AQ1=OV4UF5S<9
MM\HDA^"KK!G,"!841 ]M&$]$A6*AM[D>)*2&.H8OKBILD:]:LQ_QQ4VL8*@-
MRH=8@DX3(8A((/KPN1)T4]JZ5C\=O*DRV2'.W<N5;6:E9V!S2_8S/..R&8;L
MCD'+M_6GW1-*:=D]3+^Q/2_7[IEV8U<C[=T6GX\>&/QR\4&Q7J?KUXM.RNJK
M<MDF32M*D3;G3F_XX:1'6T68O^3TA+M[M[K_V@ ( 0(  04"_%W_V@ ( 0,
M 04"_%W_V@ ( 0("!C\"+O_:  @! P(&/P(N_]H " $! 08_ O\ +7+)8RY4
M7;=9LJ9LX6:N 373%,XH.6YTUVZH%-X3D,!BCQ :XVZ3:N\]ZGBW#%IN'E$C
MNJ8D"-EVTHLD= 3.7"F:Q<@U#PJYGS -0Q$S\8H"K"98-9%H<!KY3I$JP%'V
M'3NM,'<(?A.N6[A1&:FDC0$%ISB5T#U^F<JSE$2CF$%@Q!5:\/A,4.\0PMO'
M=>[=\RKQIN-9BP9#N^?;1[<D:E'O"J*HMWY!>'66<C<5013LX6_P3B(D#OTV
MCK*S3QDD^B7@9*Q%BY3^-7;/$*G3"MAPN+P'@.(/ILPW[OY+:\_(;<-ECNR9
M5>M6DF8".FR;I1U4P@=(^68U1*4P5N$.)HR,6EEVYG!W1CS,S)SCO-4(FF:C
MR5<NG!4J)!X ,! &M XC_"S^TWI4S%E>@;A%!4X7:*0#>@+1SP. B0[=VF0_
MO *8W!T@W()F\WM!Z]7C6RX^;HP=&1EH\M1J;E\D.8'M(O["_AU1W:;SMG]*
M-F[RVSMBO%!_O)U!NO4$NE\A^6)40*;VVF+WX=_WQF/ZOAL0'3]7I^@Z?[I%
M<T _3W<@DQ<MVYE\U5W=!F79*I)(7&):?XJ%$^-N([YV22.A=PO-&&X(O<R<
MNW8"F*6I,X9FAH]T.G36 ]/F)6T1$*81=-EDG*#A(B[=P@<JJ"Z*I0.DLDJ0
M1(HFHF(" AP$,0FR$=@MI%?<Y95:"DPW<W:M56<,4%7R[])2%.NR4204(82%
MS:WT*)AKB84BNFK1["LYN3BXV;6W>A$HR:4:MI%G#=LO$NG*R(/$U2%7  25
MMJ7&[MO1'35N,CLE^2-FP=;W:((@Z44>)$!HH$"?4$N8GXT#NQ/,9/IN$=*Q
MC#;ZD-%%W&WE5=TR6YYXD-&-(URT9H((I$!!R*QC^),4P$0MXB!U.ED<V,/^
M[6ZAL#'+^8MX%9.OY&Q,[)1V,5N&V5#)[CW VW0VDXJ.4 H@1NB9.*;ZUVHY
M#+RP$HE$IQ'@0<<<; _:-E_O+C\'"C%ND[>$1.9LV7<"T176 OEI*.@0<BW(
M<W:;+/3V#C=>U([IDB26V8X1;30.M[-$6][@ZP-S-%2P2@KIK$0$X#0*%$*T
M'AAKMI[TN3:24K'23^#4]:,UXZ4/$"@9ZPUJ,*.B>@V7!0@*D*4P=X<:3ZAM
MJ^FT=O/U8A\DZFTWTFG*)98F04CTXUMDH4$X9@J<3IB%O?B4W*VC6THG#-',
MB_;N90(CZ!FW577.@X%D^*HY\L"D3$I;Q-\084WS)=.W+1H2,YWRAMN%DYF2
M1)6BCU5RX;NF4<BDL1N4#9 *&4X]PA3!=ZP.P)AS%K%<G9-E)B#1DWY&:R[=
MR9NV,XR@$JS8Q2E44(8_=A\\A".&#R+=::2A9$4>8M2G 1;.A! ZA#-7-I@*
M8!X'(8!PXE&,&O/Z0BJ[EHU>L63@C5!$ZRJJ9I!1)!8P 3X;@$<--RAM][!Q
M<F@FZBA?O8]RX>MU!.&:*+!5;3%\' #C<->S\>H $,0ZK;IWM-LKWF1.H_=.
M!2'^3>DHF:GO#&U>M.WTATDHZ2),(I^%-21:H:9^U5I0 +.0E:?\Q,YNW#"4
MV>J#Z<W^$=#;#*G\;B2W&0 ;.Z!6P(UL<RRE>!#$H.-Q;68CF$C-@;E*Y=?.
M_D5X=\XDI!4?B%1X\4.?CV -.[$RT#XF>\'PF_[F+B#A_LXZ#_L>X?W9[CIQ
M 3[!"2B9%WN])TT<%J0X>DWUIRB%#)+HF\1#EH<AN(" X;=,=\O-1TXFEW(]
M.MW.3>&,$ZU_()9>@%2*05J5-0J9A P#E&\OHPI:%]>H12GX5L-ME$PA=_)&
MW $2(1,A>PB90(0O?P*6A0XX_P 1_P#?)G^^[CP58Z")E4Z"14R9#*$MOML4
M$+BVYAJ4[*CB-V/LL!<]1=]G&.@6Z0EOBVB@BF\GG';D$0+<"1C4"X#'[$S8
M8[>8CJ7=3/9N4-<*TO-. #6OE3'\8E$P6)@/PIE .VHCC8'[1LO]Y<?CU]SX
M^>?ZF1@K>204E-9>4DYKJ CF[@S>[,\-U+N/LQNHYH9W%H;9EVL5'HS<6O&S
MI5%XAL\>N7#5V(J-T7 NP*B)0+>D%1[<*)A]/M?K5'BH3@)6Z.\(T1$P5&H9
MKI4QOS,^]V-I]-D_$SDG0;KW@6E2^E-M.T%46"OL"=W#IT:?,BFMC>] _P#4
M-R_U*\QLC_QTG_7$GC876CI>D8FZXC;[;U1MQJG:VWK# Y54>@NBB%R\D"?$
MPT,=0"@)?-3+=SV%,;(<H+LI2-<4U<6^R*.HYX4/F*"E2G#PJ)B!@QL$J11*
MF7;C( *8:CPONX^\WX'</'"+5NF%RKARLF@@F7VG55,1,@?F..KKHDS$$;N8
MF"BXM;F#<$90\,5FR="R5.<J;DQ5PI0@FKVA4,3^V:):ITUU4.N?L0F6?GQR
MH'^4BB@99Q_X:AL)S>Z5EU(7IFK,0.S8UT4+6,[,'!:?7+X;C&8H""9:B-HK
M^&EN-[$DY-A'F<[3W"U;%>.T6YW+AQ%.D$$6Z:AP474664 I0* B(CC=<*M(
MLT94^XT7B3!9RBBY7;+QB")%6Z2IRG7#-:' UM;>_MQT- 7;8#-VDWJ"BND
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MT@4OL'*I7QG4Q#1>J;R,Y/S,9#1<&Q>-C2"QI!RFFN\.D!CF091[03KJ*&
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M@42X-UE&R3?E07"%1=N&AJP81UJ(BU!@J7 9>@'EYY.<3YX&RW98K2\^%VB
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;3__:  @! @,!/Q#W7?_:  @! P,!/Q#W7?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g514974g0124092636874.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g514974g0124092636874.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !D , # 2(  A$! Q$!_\0
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MI_K ?JRI^=>B5S&E_P#$T\:ZKJ'6*Q1;&$_[7WI/U('X44I-7EY#FKV1TP
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MWX>::\;4]%U%K"YE_P!9M4/%-[LOK[BM6*\1;>-6CF!" ']TWI]*CLKV);1
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=BB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g514974g96v72.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g514974g96v72.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  (" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @,# @(# @(" P0# P,#! 0$ @,$! 0$! ,$! ,! @(" @(" @(" @,"
M @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# __$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( 'H!$ ,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /W\H * "@ H * "@ H * "@ H * "@ H * $#+DJ&&Y<$J"
M,@'ID=J-O(/T%H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@#X+^$1;_AO3]K(;W*KX(^#X5"[E%SX:
MTLG;&6VKSD\ =3ZG/V69JW!_#?3W\3_ZDXQ?+9;;V/+P_P#R,<=TY96[?\P^
M#>O??J?>E?&GJ!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 ?!7PB_Y/T_:S_P"Q)^#W_J,Z77V69_\
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M-;^RD^2K;S]G*21AB(2G0JQ@KS4;P3T7/#WH)VZ<R5_(\B_8@^)MS\4OV;O
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MRJRE64,I!#*P!4@C!!!X(([&C:W2VWR#8;%%%"BQ0QQQ1KPL<2*B+DY.U%
MY)/ [TVV]6[ON"5MM+$E( H B,,!E69HHFF0%4E9$,J*<@JLA&Y5.3D ]S3N
MTN6[2?3I]P6UVU1+2 C6&))'E2*-97 #R*BK(X7[H=P,L!VR3CM3N[*-]([+
MHOET"R72Q)2 * /-/%OP9^$7CR[_ +0\:_#'P%XIU <?VCKWA/0]3U @ *%-
M_=63SE0 !M,F.!QQ7?A\TS+"05+#8_$4*4=H0JS4$^_(GRI^=C*6'H2ESRI1
M<]N;E7-;MS+5KRN6?"'PE^%OP_E:X\#?#KP1X1NF5D>\\.>%]%TB]='&&C>\
ML;..9T*\;3(1@]*G$9GF&,@J>*QU>O3B[J$ZLY03[J#DXIZ;I7"%"C3DYPI0
MC.UG)17-;HN:U[*^UST*N(U"@#Q_0_B?<ZC\:_'GPCO='AL$\+>"_!GC/1-6
M^V.]QKUCXCO-;T[4R;%K=%@@L-0TJ& 2QRS!VN"&V$ 'TZN7QIY5A,RA4<O;
MUJM&I'ELJ<X6<%S7=W*'O6:7DK*[YXUF\14H2BH\J4H.^LHI1N[>4I<OR\].
MR\6^ / OCZTBL?''@WPOXOLX"YM[?Q-H.EZY%;,X =[9=2M9OL[D 9:/:>!S
M7-AL;C,$Y/!XNMA7)6E[*I.GS)=)<K7,O)W1I.C2J6]I3C/E^%RBFT^Z;U3\
MU9F'X/\ @U\)/A]>G4_ WPS\">$=3:*2 ZGX?\*Z+I6I>1* )8/[0L[)+@0N
M -T8DVM@9!Q6F(S3,<73]EB<=7KT;I^SG5FX76SY&^6ZZ.UT*-"C3DIQI1C-
M)I2LN:SW7,];>5['AO[>&O6WA_\ 90^+LL\T<4NIZ1IF@V4;LJO<W6L:_I5E
MY$"DCS)1;27,VT9.RW=L?*:]7A*DZN?8+I&DJTV];+EH5.6]MKSY(+SDD88Y
M\N'LMY5**2\O:P<O_ 8*4GY)GK_[/^D7&@? KX-:-=PO;W>F?"_P':7=O*I2
M2"[B\,:8+F&16 *ND_F*00""IKS\ZG&><9I*$E*#Q>(Y9+9Q562BUZQ29I@^
M;ZKAG)<LI4X.2[-Q3:^3=CUF2**50LL<<BJRLJR(KJ'4Y5@&! 8'H>HKS4W'
M9\OIH=#2[;$G]/TQ2#;R"@##\0^&?#?BW3)=$\5^']%\3:-.R//I/B#2K'6=
M-FDB),3R6.HP30NZ$DJQ0E2>"*VP^(Q&#J*KA:]3#58II3I3E3FD]&E*#32?
M57U(G3IU(\E2$9P_EDDUIMHTUH>86/[-W[/FFW:WUC\$?A5;7<;AXYU\!^&2
M\4BG<KQ!]-(B=6 (9 "",@C%=[SS.;<O]JXJ*LUI7J1=MFFU)-IK=-ZF3PN&
M:2="$E&S2E%-)K:R=TK=.Q[/##%;110011P001I%##$BQQ0Q1J$CBBC0!8XU
M10JJH    &!7EMMMMMMMW;>]^K;[G0DDDDK);(DI % !0 4 >;_#UY'OOB5O
MEED$?Q'U*.,22R2"*-?#WADB.(.Q$409F.Q-J@LQQECGW<[48TLAY8J-\LHM
MV25W]8Q6KLE=Z;N[T6NA\YP\Y.MQ)>3ERYQ62NV[+ZK@]%=OE2NW965VW:[9
MZ17A'T84 ?&WQ9T^Q^(W[5G[//@*5O-M_A;H/C/X\^(+*5"D3RP7&D^$/ -Q
M;R,-LMS;^([B_N&1=Q1+<$[=ZFOJLME/ <-YSCN6WU^K2R^C--74N2=3$QE'
M?EGAYN*>GO6U=FGYM?EKX[#X?1^PBJU2+3^'FO2<7=+FC6HQ?5VOM>Y]D]/;
M]*^5/2V\@H * //OAF[OX<O#)))(P\7>/%#2R22L$3QKKZ1H&D9B$1%554'"
MJH50  ![.?)1QU-1BHKZGE[LDDK_ %'#MNRMJWJWNWJ]3P.&W)Y=5O)R:Q^9
MJ\FV[+,<4DKMO1+1+9))*R1Z#7C'OG+>)?%ECX8.GI=6FH7DVIR7$=K!IZ6C
M28M8EEGDD:]O+:-$563_ ):%B6X4X./1R_+*V8>V=*I3HPPZBY2JN:7OMQBD
MJ<*DFW9_9LK;GE9GF]#*_J\:M&K7GB7-0A15._[N*E)MU*E**237VFVWHMSR
M'QS\0K:]/@SR-)\1VGV3QYH%Y-N?2(OM,$$=^'M!]EUUO,:3>IV3;8CL^=A@
M9^HR?(JE%9JIXG"U?:9?B*<;*L^23=.T_?PZLHV>L+S5_=3U/C\\XBI5WDOL
M\'C*'L,TPM65WAX\\8*K>FO9XJ7,Y77NSM!V]YK0[O\ X6AIW_0N^)?^^?#W
M_P T->/_ *N5_P#H.POWXG_YF/=_UIP__0MQOW8/_P";#"N/B19'Q+I%R-$\
M2+%#H/B*%[?.A@R//J/A9HY0BZ_Y3"-;>5=SL&7[0 @(9]O7#A^LL!B:?US"
M\TL1A9*7^T:*%/%IQO\ 5N9<W.G9*SY?>::C?AJ<2T/[2PE7ZAC%&&&Q<7#_
M &6[<ZN":E98OE?*H25VU)<RY4TY6W?^%H:=_P!"[XE_[Y\/?_-#7)_JY7_Z
M#L+]^)_^9CN_UIP__0MQOW8/_P";#2\/^/\ 2?$&M2:!#8ZM8:E'I;ZPL6H1
M6(CDL8KJ"RDDCEL-0NE#K<7$0V.4)#$@$ US8[),3@<+'&2K4:U"554+TG4O
M&HX2FDXU*=-V<8/5771G7EW$&$S#&2P$*%?#XF%!XA1JQI6=.-2--M2I5JJN
MI3BK.SMJCNJ\<]T\[^%CR/X05I9)96_X23QN-\TCROM3QKX@1%WR,6VJBJJK
MG"JJJ %  ]OB%1CF<E&*BEAL!I%**_W'#-Z)):O5]WKN?/<+.3R>#E*4G]:S
M'64G)V68XM+5MNR2LET226B1Z)TKQ#Z$* /S\_:TU#Q-\#OBG\*_VKM#L&U;
MPEX7TF_^&?QBTFVN[6WU&X\#Z[JL-]H]SI]O=SPKJ$UGK-S>7*0I(K?:8;$/
MBWDN)(/LN'8TLUR['\.U9<E6K/ZWA9-2<8584[5)R<;\MJ=.,7[LFZ<ZO*N=
M03\[%J5&O2Q4=>5*#6FJN[4]5>T^=R3YHJ,Z=-RO&Z/M[P=XO\/>/O"^A^,O
M"E^=3\.>(["'4]'OS:7MB;JSGSY<IL]0MX+FW)*L-DT4;#'3U^4Q.&K8+$5<
M+B8>SKT'RSC>,K.U]XMQ>C3T;.ZG.-2"G!WB]M+;.ST?9JQTM8;%GYM_'^V_
MX:G_ &@/AS^S_P"'KK[3\/\ X1ZO#\1_CK+*CV<0NX9'M/#OAJW@OA!/J5S-
M:KJ-NT]BES;Q)XE65I-]H\8^ZR?FX<R?%9S67)B\QC[' I.\N5>\JC<>:"A[
M5*HX5.63^JV7+SP<O*Q*CC:\,-'WH4N9332Y5=<M3?EDI*G+V<90;2==MJ48
MRY?TD P,#@#@#I@#H,5\+L>KMY6.<\8%D\)>*61F1E\.:V5=&9'1ETRZ*LCH
M0R," 0P(((R*[LK2_M/+E9-?6L/HU=?Q8:-/1KNF>;G+<<HS5IN+C@\39IM-
M-49V::LTUT:U1%X'+-X*\'LS.[MX7\/EGD=I)'8Z3:%F>1R6=R<DLQ)))).3
M5YNE'-LS22BHXO$I))))>VG9)*R271+1$Y&W_8N3MMM_4L)=MMN_L*>K;NV^
M[>K.HKSCU H \WU]Y%^)GPYC6258VT7Q^7B6618I"D?AC8TL2L$E9-S;2ZDK
MN;;C<<^[@DO[ SU\JO&MEUFTKKWL5>S:O&]E>S5[*^Q\YF#:XEX<2E)+ZOFE
MXJ347:.#M>*=FUT;3M=VM=GI%>$?1A0 4 % !0!YI\._^/\ ^)G_ &4K4_\
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MQS?C'_D4/%7_ &+>N?\ ILNJ[\K_ .1GEW_85A__ $[ \W.?^1/FW_8'BO\
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M_"2A_P#(!_PK#X<?]"'X1_\ ">TK_P"1:/[>SS_H<8W_ ,*:W_R8?ZL\._\
M0BP'_A)0_P#D#C?$O@?P=HFIZ->67PHL=>T\V>LVU[9:!X=\.R/%=RRZ/)87
M-S;WTUJC*L5OJ$:NK,R&9@!B1L^KE^:YGB\/BJ57B.I@J\9T)TYXC%8F*<(Q
MKJI&$J:J-/FE2;BTD^5/>*/%S+)<GP6)P=6CPK3Q^&=/$0J4L+@\))JHY8>5
M*<X594HM*,*L8R3;BY-6M)F3]A\$C_FWC5^/^I/\#]O^XY73SYLO^:VHZ?\
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M%XG_ -/3.O(M,DR?I; X3_TQ3.IKSCU H * "@ H * "@ H * "@ H * "@
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
6* "@ H * "@ H * "@ H * "@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
